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Abstract
This thesis describes the results of a study exploring patient access to percutaneous 
coronary intervention (PCI) in a rural-urban setting in northern British Columbia,
Canada. It specifically examines: 1) whether longer times to treatment (>120mins) are 
associated with higher adverse outcomes (death, re-infarction, heart failure, or stroke) in 
the UA, NSTEMI and STEMI groups within 30-days and 1-year of hospital admission 
and 2) whether patients most at risk using the Global Registry of Acute Coronary Events 
(GRACE) risk score receive PCI faster in the UA, NSTEMI and STEMI groups. Data 
were collected through retrospective medical chart reviews. Times to treatment and 
adverse outcomes data are provided although quantitative analysis of this association was 
not performed. It was determined that the only significant predictor of time to PCI was 
age and patients were not transferred according to their risk status. Thus it can be 
concluded that this exploratory study provided valuable real-time feedback for cardiac 
services in this region and is a basis for further longitudinal investigation in this area.
Keywords: percutaneous coronary intervention, thrombolysis, unstable angina, segment 
elevated myocardial infarction, non-segment elevated myocardial infarction, Global 
Registry of Acute Coronary Events, GRACE, risk score, GRACE risk score
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GLOSSARY
Acute coronary syndrome (ACS): umbrella terms for the clinical signs and symptoms of 
myocardial ischemia; unstable angina (UA), non-segment elevated myocardial ischemia 
(NSTEMI), and segment elevated myocardial ischemia (STEMI)
Acute myocardial infarction: chest pain due to the sudden reduction of blood flow to the 
heart
Atherogenic dyslipidemia: a metabolic risk factor characterized by the serum elevation of 
triglycerides, apo B and low density lipoproteins (LDL), as well as a decreased level of 
high density lipoproteins
Atherosclerosis: plaque buildup which can lead to the narrowing of coronary arteries
Angioplasty: also known as balloon angioplasty, percutaneous coronary intervention, 
balloon angiography, coronary angiography
Catheter: a small, narrow tube that can be inserted into a body cavity, duct or vessel
Congestive heart failure (CHF): condition that occurs when the heart is unable to provide 
sufficient blood flow to maintain the needs of the body and vital organs
Coronary artery bypass graft (CAGB): a type of open-heart surgery in which a vein is 
removed from an area such as the leg is stitched to the aorta and coronary artery to create 
a new path for the flow of oxygenated blood to the heart
Coronary heart disease (CHD): a disease of the coronary arteries in which plaque buildup 
obstructs the supply of oxygenated blood to the heart
Coronary heart disease: narrowing or blockage of the arteries which supply blood to the 
heart
Door-to-balloon time (d2b): the time elapsed between the patient presenting to the 
emergency department with ACS symptoms to the point of PCI initiation
Fibrinolysis: see thrombolysis
Global Registry of Acute Coronary Events (GRACE): a risk stratification tool used to 
predict both in-hospital and six month mortality post acute coronary syndrome 
presentation
Myocardial infarction: a heart attack
Myocardial ischemia: a sudden reduction in blood flow to the heart
Non-segment elevated myocardial ischemia (NSTEMI): the partial occlusion of a 
coronary artery
Percutaneous coronary intervention: a non-surgical procedure which uses a catheter to 
place stent to open blood vessels in the heart which were occluded by plaque
Peripheral vascular disease (PVD): the obstruction of arteries (other than coronary) from 
plaque buildup and thrombus formation among other causes
Segment-elevated myocardial ischemia (STEMI): usually indicative of a full occlusion of 
a coronary artery which can lead to the necrosis of the myocardium
Thrombolysis: the use of pharmacological agents to break up blood clots, often 
interchangeably used in the literature with the term, fibrinolysis
Thrombolysis in Myocardial Infarction (TIMI): a risk stratification tool used to predict 
mortality post acute coronary syndromes
Thrombus: a blood clot
University Hospital of Northern British Columbia (UHNBC): the largest regional hospital 
in Northern British Columbia, located in Prince George, also serves as a clinical teaching 
centre for the Northern Medical Program offered jointly through the University of British 
Columbia and the University of Northern British Columbia
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CHAPTER ONE: INTRODUCTION
Cardiovascular disease can be defined as a group of disorders that affect the heart 
and blood vessels (Public Health Agency of Canada, 2009). Cardiovascular disease is 
one of the leading causes of death for all Canadians (Statistics Canada, 2012). In fact it is 
estimated that every seven minutes, a Canadian dies due to heart disease or stroke (Heart 
and Stroke Foundation, 2012). Economically, CVD and stroke cost the Canadian 
economy over $20.9 billion annually in physician services, hospital costs, lost wages and 
decreased productivity (Charles River Associates, 2010; Heart and Stroke Foundation, 
2012).
Coronary heart disease (CHD) is the most common form of CVD. CHD can lead 
to an acute myocardial infarction (AMI), or chest pain due to a sudden reduction in blood 
flow to the heart muscle. This restriction in blood flow results from a buildup of plaque 
deposits in the coronary arteries that are responsible for supplying oxygenated blood to 
the heart. It is estimated that there are nearly 70,000 AMIs a year in Canada 19,000 of 
which are fatal (Tu et al., 2003; Healthy People, 2010) and a large number of Canadians 
suffering from an AMI die before they are able to receive medical care.
Acute Myocardial Infarction most commonly presents in the form of acute 
coronary syndrome (ACS). Acute coronary syndrome is the umbrella term given for the 
clinical signs and symptoms of the following conditions associated with myocardial 
ischemia including: unstable angina (UA), non-ST-segment elevation myocardial 
infarction (NSTEMI), and ST-segment elevated myocardial infarction (STEMI) 
(Overbaugh, 2009). These conditions represent a continuum of acuity and increasing
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intensity from unstable angina to ST-segment myocardial infarction. Unstable angina and 
non-ST segment elevated myocardial infarction typically arise from a partially occluded 
coronary artery whereas ST-segment elevated myocardial infarction is indicative of a full 
occlusion of the artery and typically results in a full thickness infarction (Overbaugh, 
2009).
Risk factors
There are a number of established cardiometabolic risk factors for CVD. These 
include: smoking, Type 2 diabetes mellitus, alcohol consumption, a lack of physical 
activity, elevated levels of serum cholesterol, and high blood pressure (Tanuseputra et al., 
2003). According to recent statistics by the Heart and Stroke Foundation (2012) of 
Canada, at least nine out of ten Canadians have at least one or more of these risk factors. 
In addition to these factors, risk can also be increased due to certain influences such as 
sex (male), age (45 and over for males, 55 and over for females), family history, prior 
cardiac history (prior myocardial infarction, congestive heart failure (CHF), prior 
percutaneous coronary intervention (PCI), prior coronary artery bypass graft (CABG), a 
history of stroke and/or transient ischemic attack (TLA), atrial fibrillation (AF), and 
peripheral vascular disease (PVD)) and ethnic background. For example, research has 
shown that those of South Asian descent have much higher rates of cardiovascular 
disease when compared to other ethnic groups (Anand et al., 2000; Gupta et al, 2006; 
Joshi et al., 2007).
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Geography and the link to cardiovascular disease
Canada is recognized by many around the world for the health care system and 
related services that it provides its citizens (Romanow, 2002). One of the core principles 
of the publically funded Canadian health care system is that of universal access to 
medically necessary care. While universal access to health services is perceived as one of 
the most important and underlying values of the system, the fact remains that not all 
Canadians are true recipients of universal and equal access to these services.
In Canada, the vast geography of the country makes it a challenge to deliver 
access to health care services and resources on a uniform basis. It is often seen that the 
larger, more urban centres are often equipped with highly advanced technology and a 
variety of specialized services and service providers. This is in stark contrast to Canada’s 
rural and remote regions where health care services are often limited and hard to come by 
(Smith et al., 2008).
In situations like this, patients in rural settings needing more advanced health care 
services are often faced with the prospect of being transferred to larger centres to receive 
care. While medically necessary procedures including interventional cardiac services, are 
covered by provincial health care plans in Canada, the transfer of patients to these centres 
involves many variables that can affect patient outcomes (Pilote et al., 2004). These 
include, insufficient staffing levels, a lack of specialized services, and increased wait 
times to receive access to services (Ross et al., 2006).
One of the main concerns to health care providers is the impact of wait times on 
patient health outcomes. This is also true for higher-level life saving cardiac services
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which are more often readily available in only the larger, more urban centres in Canada 
(Pilote et al., 2004; Patel et al., 2010). For example, primary percutaneous coronary 
intervention, is considered the reference treatment for patients suffering from acute 
coronary syndrome, in particular, STEMI (Zijlstra, 2003). It is considered to be superior 
to the pharmacological option of thrombolysis with respect to decreasing rates for both 
patient mortality and morbidity (Antman et al., 2008; Van de Werf et al., 2006; Keeley et 
al., 2003; Boersma et al., 2006). There are however major barriers to the implementation 
of widespread use of primary PCI (PPCI). These barriers include, the delay due to the 
lack of centres capable of performing PCI and long distances for transport required for 
access to the procedure (Sorensen et al., 2011).
Although not explicitly thought of as a risk factor, the concept of geography has 
been identified as a determinant of health. It can also have a profound influence on risk 
status for cardiovascular disease. Those living in rural areas are considered to be at higher 
risk for the development of cardiovascular disease. It is also a well-documented fact that 
those living in rural areas have poorer health status when compared to their urban 
counterparts (Romanow, 2002; Pong et al., 2009). Rural dwelling individuals have been 
documented to display a greater incidence of unhealthy lifestyle behaviors as compared 
to those in urban settings (DesMeules & Pongo, 2006; Pamplon et al., 2006). This often 
results in them having higher frequencies of the classical CVD risk factors such as 
diabetes, physical inactivity, and obesity.
In addition to increased levels of risk factors, risk is further exacerbated due to the 
unique challenges that rural individuals face when accessing health care services for their 
conditions. For example, it is a well-known fact that rural areas face challenges in the
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recruitment of physicians and other allied health care professionals such as 
physiotherapists, and medical diagnostic technicians (Fleet et al., 2013). This often 
directly impacts the availability of diagnostic services and advanced level care 
procedures. As a result, rural patients are faced with the prospect o f having to travel for 
their health care needs. This leads to the added burden of travel costs, and added wait 
times among other issues. As well there may be additional risk associated with moving to 
an urban centre (Sibley & Weiner, 2011). For example, the risk of travelling long 
distances in less than ideal weather conditions. Furthermore, patient outcomes are 
generally worse for those living in rural areas as highlighted by the increased mortality 
rates for cardiovascular disease in rural patient populations (Filate et al., 2003;
DesMeules & Pongo, 2006).
Symptoms of acute coronary syndrome
Acute coronary syndrome, more commonly referred to in layperson’s terms as a 
heart attack, presents with some common symptoms. These include: chest pain or 
discomfort, which is often described as involving a sense of crushing, tightness or 
pressure, pain or discomfort in one or both arms, neck, jaw, back or stomach, shortness of 
breath, a feeling of dizziness or lightheadedness, nausea and/or vomiting, and sweating. 
However, ischemia can also occur without any of these typical signs or symptoms. It is 
referred to in medical terms as ‘silent ischemia’ (Overbaugh, 2009). Silent ischemia is 
more common in the elderly (65 years and older), those with diabetes, and the female sex. 
The outcomes for silent ischemia are often worse as the absence of symptoms results in 
delays for seeking treatment. This delay in treatment seeking often leads to lower rates of 
recovery and higher rates of mortality (Maron & Hochman, 2013).
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Diagnosis and management of acute coronary syndrome
The protocol for ACS diagnosis at hospitals in British Columbia is based on the 
guidelines established by British Columbia’s provincial government. These provincial 
guidelines are based on those developed jointly by both the American Heart Association 
(AHA) and the American College of Cardiology (ACC). These guidelines split patients 
into the following categories namely, definite ACS and possible ACS.
When a patient presents to the emergency department with symptoms of ACS 
such as chest pain or difficulty breathing, there is a set of steps performed to determine 
whether it is ACS. These steps are established by the BC Medical Association and are 
presented in Figure 1. (pg. 10). ACS is essentially a working diagnosis and there are a 
series of tests and procedures performed to pinpoint the diagnosis and specifically define 
the type o f ACS.
These patients are triaged according to the Canadian Triage Acuity Scale (CTAS). 
If the patient complains of typical ACS symptoms, and more specifically chest pain, they 
are triaged as a 1 (resuscitation required), 2 (emergent care required), or sometimes a 3 
(urgent care required). These patients are given high priority and are evaluated on an 
urgent basis. Diagnostic test for ACS involve two preliminary tests including a blood test, 
and a 12-lead electrocardiogram (ECG) and also involves evaluation by a physician.
Diagnosis of an acute myocardial infarction is based upon the following criteria 
being met: detection of a rise and/or fall of cardiac biomarkers, specifically troponin. At 
least one value should be above the 99th percentile, plus at least one of the following: 
symptoms of ischemia, ECG changes indicating new ischemia; ST elevation; new left
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bundle branch block, new pathological Q waves in the ECG, and /or imaging showing a 
new loss of viable myocardium or new regional wall motion abnormality.
Myocardial ischemia causes tissue damage and myocardial cell death resulting in 
the release of cardiac biomarkers in the blood, specifically troponins, TnT and Tnl, and 
CK-MB). Testing for these biomarkers is perfomed alongside a 12-lead ECG and 
physician evaluation to diagnose ACS. The cardiac troponins are considered to be more 
sensitive and more specific in the detection of myocardial damage, and they are measured 
upon patient presentation and six to eight hours post chest pain onset.
A diagnosis of STEMI is made when cardiac biomarkers are elevated and 
electrocardiography reveals that there is ST-segment elevation or new left-bundle branch 
block whereas a diagnosis of NSTEMI is made when cardiac biomarkers are elevated and 
electrocardiography reveals there is ST-segment depression or T-wave inversion. 
Unstable angina is diagnosed when cardiac biomarkers are not elevated and 
electrocardiography findings reveal ST-segment depression or T-wave inversion.
Management of STEMI
Patients with STEMI are treated with the intent of reperfusing the ischemic 
muscle. The reference treatment for STEMI is PCI while thrombolysis is now only used 
in hospitals without PCI capabilities or in instances when PCI cannot be delivered in the 
target ‘door-to-balloon’ (d2b) times of 90 minutes or less (Levine et al., 2011). The 
ACC/AHA guidelines recommend that patients who receive thrombolytic therapy are 
transferred to a PCI capable centre following the treatment. Patients with STEMI 
presenting to UHNBC are transferred via British Columbia (BC) air ambulance, a flight
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with duration of about an hour to one of the five cardiac catherization labs in the 
province. These include: Vancouver General Hospital (VGH) or St. Paul’s Hospital 
(SPH) in Vancouver, Royal Jubilee Hospital (RJH) in Victoria, Kelowna General 
Hospital (KGH) in Kelowna, or Royal Columbian Hospital (RCH) in New Westminster 
(Figure. 2). This inter-hospital transfer of patients to provincial cardiac catherization labs 
is overseen by BC Bedline, formerly known as the Patient Transfer Network (PTN).
Management of NSTEMI/UA
Patients with NSTEMI or UA are treated for acute myocardial ischemia (British 
Columbia Medical Association, Guidelines and Protocols Advisory Committee, 2008). 
This treatment involves: bed rest with continuous ECG monitoring, oxygen for patients 
with respiratory distress or oxygen levels of less than 90%, sublingual nitrates for those 
experiencing continuous pain or intravenous nitrates for those with stable blood pressure 
readings or those unresponsive to sublingual nitrates or beta-blockers (Fitchett et al.,
2011; Wright et al., 2011). Percutaneous coronary intervention (PCI) may also used for 
NSTEMI/UA patients though less frequently than those with STEMI (Fitchett et al.,
2011; Wright et al., 2011). An alternative and more frequently used approach for 
NSTEMI and UA patients is the use o f low molecular weight heparin, aspirin and anti­
platelets agents such as clopidogrel, as well as statins and ace inhibitors. Along with beta- 
blockers these have been shown to decrease mortality in these patients (Wong et al., 
2003). However, if considered suitable candidates for PCI, patients with NSTEMI or UA 
are also transferred to provincial cardiac labs like those with STEMI. Although the 
optimal time frame for maximum therapeutic benefit from PCI for these patients has not
8
been well-defined however early or immediate catherization is recommended (Jneid et 
al., 2012).
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Treatment options
The current ‘gold standard’ for treatment of ACS is percutaneous coronary 
intervention (PCI) with respect to decreasing rates for both patient mortality and 
morbidity (Antman et al., 2008; Van de Werf et al., 2006; Keeley et al., 2003; Boersma et 
al., 2006). It is also known as balloon angioplasty, coronary angioplasty, coronary 
balloon angioplasty, coronary transluminal angioplasty and coronary artery angioplasty. 
Percutaneous coronary intervention (PCI) is a non-surgical procedure that is used to 
widen coronary arteries occluded by plaque deposits. It is performed through the use of a 
thin catheter. The catheter is inserted through the femoral or radial artery and is used to 
place a stent in the occluded blood vessel. When the stent tip is in place, a balloon on the 
end of the stent is inflated. The inflation of the balloon compresses the plaque and 
expands the stent. When the plaque has been compressed and the stent has fully expanded 
into place, the balloon is deflated and withdrawn (Heart and Stroke Foundation, 2012). 
Current ACC/AHA guidelines consider primary PCI (PPCI) to be most effective when 
delivered in the ‘door to balloon’ time of 90 minutes. In centres where primary PCI is not 
feasible, a ‘door to balloon’ time of 120 minutes is recommended.
Not all hospitals have on-site cardiac catherization labs. In fact some hospitals do 
not have access to catheriztion labs in their region and require patient transportation 
across large distances to receive required care. For hospitals not equipped with 
catherization facilities to perform PCI, pharmacological measures are the next best 
option. These measures, vary depending on diagnosis of STEMI or NSTEMI/UA. For 
patients with STEMI, thrombolysis or fibrinolysis, is the preferred treatment and it 
commonly involves the administration of tissue plasminogen activators (tPAs) for the
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purpose of dissolving the artery obstructing clot. According to guidelines developed by 
the American Heart Association, thrombolytics are most effective when received within 
the first 90 minutes of presentation and greatly increase the patient’s chances of survival 
and recovery if administered within 12 hours of symptom presentation (Levine et al., 
2011).
Thrombolytics are used only in instances when not countra-indicated. Such 
countra-indicative factors are usually present in high-risk patients where the risk of 
administering treatment outweighs the potential for benefit to the patient. Such factors 
include: recent head trauma, bleeding problems, ulcers, pregnancy, recent surgery, 
uncontrolled high blood pressure and whether the patient is on blood thinning agents.
For patients suffering from NSTEMI or UA, pharmacological options include: 
low molecular weight heparin, aspirin and anti-platelets agents (eg. clopidogrel) as well 
as statins and ace inhibitors. Along with beta blockers these have been shown to decrease 
mortality and the anti-platelet agents and heparin are probably the most important 
therapies. There is no documented benefit in the literature from thrombolysis in these 
types of ACS (Levine et al., 2011). However, pretreatment with intensive antithrombotic 
therapy may diminish thrombus burden and “passivate” unstable plaques, improving the 
safety of percutaneous revascularization and reducing the risk of peri-procedural 
ischemic complications (Jneid et al., 2012).
Knowledge gaps
While recent advances in pharmacology and revascularization procedures have 
dramatically improved health outcomes for patients with ACS both the incidence and
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prevalence of ACS is increasing and is further expected to increase (Grundy et al., 2004). 
This increase is thought to be in large part due to the exponential increases in obesity and 
Type 2 diabetes mellitus expected worldwide (Lakka et al., 2002; Malik et al., 2004; 
Booth et al., 2006; Donahoe, et al., 2007; Fox et al., 2007). This phenomenon is 
occurring in both, developed and developing countries alike. Rural and northern areas are 
being the most impacted due to poorer health status and health care resource limitations 
(Arcury et al., 2005). With the rise in incidence there is an increased stress on the health 
care system and resources. In such instances it is crucial to find ways to maximize the 
effectiveness of these resources and to use them in the most efficient manner possible. To 
date, there is a scarcity of research that has been conducted on this topic area.
The University Hospital of Northern British Columbia
The University Hospital of Northern British Columbia (UHNBC) is located in 
Prince George, the capital of northern British Columbia. It is a health care facility with 
over 200 acute care beds, and is the largest hospital in the entire northern region of the 
province (Northern Health Community Health Information Portal, 2013). It falls under 
the jurisdiction of the Northern Health Authority, one of the six regional health 
authorities in the province of British Columbia (Figure 3.). The hospital serves as a 
regional hub for health services and serves a city population of 80,000 and an estimated 
300,000 that live in the more rural areas of the north (Rural Coordination Centre of 
British Columbia, 2013).
The UHNBC provides services that are not readily available in smaller 
community hospitals including: a variety of diagnostic services, radiology, neonatal
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intensive care, trauma care, as well as clinics for chronic ailments and maternity services. 
Patients from other areas within the Northern Health Authority boundaries can be sent to 
UHNBC for evaluation, stabilization or further treatment. Furthermore, some may be 
transferred from other community hospitals to UHNBC to await transfer to a larger 
facility in the Lower Mainland for services not available in the north. In addition to 
providing health care services, the hospital serves as a clinical teaching campus for 
students in health professions such as physiotherapy, medical laboratory technology and 
medicine.
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Figure 3. Areas served by the Northern Health Authority (reprinted with 
permission from UBC Faculty of Medicine, 2014)
Rationale for the study
This study aims to address the issue of access to cardiac catherization services, 
specifically PCI for patients in northern British Columbia. It responds to an important 
health care need in this part of the province. This study aims to explore the issue of 
access to PCI with a high-risk population with unique geography and health needs. 
Patients presenting to UHNBC are transferred for care to hospitals equipped with cardiac 
catherization labs. While most catherization centres recognize the urgency for treatment 
of patients with ACS, there is lack of a standardized or formal process for assigning 
patient priority. Instead this is done most often through either a formal or informal triage 
process. It is a process that often relies highly on physician judgement and can lead to 
some centres allocating the next ‘available slot’ to patients with ACS requiring the 
procedure. In fact there is little evidence to support that any centre risk stratifies patients 
for the urgency of transfer or has a system to ensure appropriate and timely triage of 
patients with ACS (Patel et al., 2010).
The rationale for studying patients presenting to UHNBC with ACS varies. To 
begin with, ACS is a fairly common presentation at the emergency department at 
UHNBC. In fact, northern BC has the highest AMI hospitalization rate and highest CVD 
related mortality rate in all of British Columbia (Cardiac Services British Columbia, 
2010).
Secondly, based on prior estimates of ACS data for UHNBC, it was expected that 
the sample size would be adequate for this study. It was estimated that there would be
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approximately 250 patients presenting to UHNBC with ACS for the one year time period 
of January 2012 through to December of 2012.
Thirdly, the population of northern British Columbia is considered to be a high- 
risk group for ACS. Higher rates of traditional risk factors, geographical barriers, and 
limited health care resources all contribute to this heightened risk status. It is therefore 
important to study this population and it is safe to assume that carrying out this project 
will help to inform cardiac care for future ACS patients at UHNBC.
Fourth, UHNBC currently has no facilities for PCI or angiography, which the 
literature regards as the ‘gold standard’ treatment for ACS STEMI (D’Souza et al., 2011). 
Patients with ACS who require this treatment are sent down to the hospitals in the Lower 
Mainland namely, Vancouver General or St. Paul’s. This is in contradiction to the 
literature as the literature states that to be the most effective, PCI should be delivered in 
the ‘door to balloon’ time of 90 minutes (D’Souza et al., 2011). However, it is obvious by 
just the flight duration from Prince George to Vancouver of over just over an hour that 
achieving this target time is effectively impossible. Therefore research on this topic will 
help determine the impact of those wait times and allow for insight into areas of potential 
improvement in current practices.
Finally, it is important to note that given a Canadian context, the vast geography 
and population dispersion, we cannot justify the creation of PCI centres in every hospital. 
The primary objective here was to see whether when thrombolysed (or not), longer times 
to treatment for PCI are associated with worse patient outcomes and to determine
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whether patients are transferred according to their risk status. This will help to provide 
direction for the future.
Research objectives
The proposed study has the following research objectives. They include: 1) to 
determine through multiple linear regression whether longer door-to-balloon times 
(>120mins) are associated with higher rates of adverse outcomes (death, re-infarction, 
heart failure, or stroke) in the UA, NSTEMI and STEMI groups within 30-days and one- 
year of hospital admission and 2) to determine through multiple linear regression whether 
the patients most at risk using the GRACE score receive PCI faster in UA, NSTEMI or 
STEMI groups
Significance of the research
This research responds to an important health issue of cardiac care in a setting 
with a high-risk population and limited access to evidence-based treatment. It also has the 
potential to drive changes in the clinical setting that may aid in improving patient 
outcomes. There is no doubt that there has been much research into the importance of 
rapid access to PCI, as well as the risk stratification of ACS patients using GRACE risk 
scores. Despite all this research, there remains a gap in the literature when it comes to 
studying these topics from a rural point of view. In fact the available research is often 
focused on centres where access to PCI is readily attainable. Furthermore, the study 
populations in this research are often urban dwelling and have a better overall health 
status as well as a different set of risk factors than their rural dwelling counterparts. This
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is of significance as this limits the generalizability of the findings of these studies to the 
rural population.
Patients living in rural settings face unique health care challenges. These 
challenges can be in the form of poorer health status and health outcomes or limitations 
in access to health care services (Romanow, 2002; DesMeules et al., 2006). Addressing 
the aforementioned research aims from a rural standpoint will offer a relevant perspective 
to the issues faced by patient with acute coronary syndrome in a rural health care setting 
with particular health care needs.
A northern perspective
Northern British Columbia is a resource rich area o f the province with an 
abundance of thriving forests, lakes, rivers and wildlife. This region is a major driving 
force behind the provincial economy. Northern BC is highly industry based with a heavy 
focus on forestry, mining and fishing. The northern region covers 2/3 of the northern part 
of the province, equivalent to area the size o f France (de Leeuw, 2011). It is home to a 
population of approximately 350,000, most of which live in rural or remote areas. This 
combination of a vast geographical landscape coupled with an unevenly distributed rural 
population makes it difficult for efficient health care service delivery. In addition to this, 
the high-risk lifestyle associated with industry jobs that are dominant in this region can 
have additional negative impacts on the health status of this subset of the population 
(Pamplon et al., 2006).
The population in northern British Columbia is considered to be at high-risk for 
ACS. Factors contributing to this increased risk include high rates of obesity, diabetes,
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smoking, alcohol consumption and physical inactivity. According to a recent report by 
Cardiac Services British Columbia (2011), northern British Columbia has the highest 
diabetes, obesity and smoking rates in the entire province. This region comes second 
highest for physical inactivity, and third highest for hypertension and heavy alcohol 
consumption (Cardiac Services British Columbia, 2011). This part of the province has a 
large concentration of First Nations people. This is of significance as heart disease is the 
leading cause of death among First Nations people (Heart and Stroke Foundation, 2012). 
Thus this makes it all the more important to study this topic from a northern point of 
view.
In addition to the effects of a northern and rural geography, there are additional 
factors that can impact the health of northern dwelling populations (University of 
Northern British Columbia, 2013). These factors include: physical and emotional 
isolation, a transient population, and seasonal employment alongside the fluctuation of a 
resource based economy, and a harsh climate. Additionally, the use of population, which 
is low and dispersed, can work to further disadvantage this community when it is used 
determine public investment in services as well as resource allocation, including health 
care services for this area.
This thesis is organized into six chapters. The next section of this thesis reviews 
existing literature on the use of PCI and the concept of risk stratifying patients with ACS 
using the Global Registry of Acute Coronary Events (GRACE) risk score. The approach 
used to risk stratify patients is described. Findings related to time to PCI and risk status of 
patients are summarized. The review of existing literature is followed by a description of 
the methodological and analytic procedures as well as a presentation of the results of this
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research. Following this a discussion of the findings is presented and the thesis concludes 
with a discussion of implications, recommendations and directions for future research.
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CHAPTER TWO: LITERATURE REVIEW
A review of the literature was conducted in relation to the two research questions 
that will be examined in this study. These include; the importance of timely access to 
percutaneous coronary intervention (PCI) for patients with ACS, and value o f performing 
the risk stratification of patients with acute coronary syndrome using the Global Registry 
of Coronary Events (GRACE) risk scores, (see Appendix G/H for summary tables).
It begins with a discussion of the importance of timely access to primary 
percutaneous coronary intervention (PPCI) and moves onto discuss options in the event 
that PPCI is not available or cannot be conducted in the recommended time frame.
Finally the GRACE risk score is introduced and its use for ACS patients is discussed. 
This is followed by a discussion on validation studies conducted on the use of the 
GRACE risk score for ACS patients and their findings.
Search strategy
A review of the literature was conducted through electronic health databases. For 
both research questions the databases used included: CINHAL, Medline Ovid, PubMed, 
and Cochrane Reviews. These databases were used as they were found to be most 
relevant to the research in question and evidence-based medical practice trials. In 
addition to this, an examination of grey literature available through Google Scholar was 
conducted to identify any missed relevant literature. Searches were limited to 2002-2013, 
trials involving humans, and publications in the English language, For the first research 
question, search words included: percutaneous coronary intervention, coronary
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intervention, balloon angioplasty, transluminal coronary angioplasty, angioplasty, 
thrombolysis, fibrinolysis, time to treatment, door to balloon time, primary PCI, 
facilitated PCI, rescue PCI. Searches were filtered using the restriction of randomized 
control trials. For the second research question search terms included: Global Registry of 
Acute Coronary Events, GRACE, GRACE risk score, risk score, risk stratification, acute 
coronary syndrome(s).
Importance of timely access to percutaneous coronary intervention
Percutaneous coronary intervention (PCI) is a non-surgical procedure that helps to 
restore blood flow to the affected artery. It is essentially used to widen coronary arteries 
occluded by plaque deposits. It is performed through the use of a thin catheter that is used 
to place a stent in the occluded blood vessel. When the stent tip is in place, a balloon on 
the end of the stent is inflated. The inflation of the balloon compresses the occluding 
plaque and expands the stent. When the plaque has been compressed and the stent is in 
place and has fully expanded, the balloon is deflated and withdrawn (Heart and Stroke 
Foundation, 2012).
Current ACC/AHA guidelines consider PCI to be most effective when delivered 
in the ‘door to balloon’ time of 90 minutes. However, this target time is rarely achieved, 
especially in hospital settings without on-site cardiac catherization labs (De Luca et al., 
2004). Instead facilitated, PCI post thrombolysis, or rescue PCI in the event of failed 
thrombolysis, is performed in such cases. ACC/AHA guidelines consider a ‘door to 
balloon’ time of less than 120 minutes acceptable in such conditions (Levine et al., 2011). 
Still this recommended target time can be hard to achieve given the real-life context 
(McNamara et al., 2006; Rathore et al., 2009). Futhermore, the generalizability o f these
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guidelines may be limited in Canadian context as they are reflective of the American 
landscape. The United States has a different geography, a much larger and more 
distributed population as well as a health care system that is very distinct from the 
publicly funded system in Canada thus expecting strict adherence to one set of guidelines 
for both nations is unfair and unrealistic.
Primary PCI has shown to offer more benefits as compared to fibrinolysis for 
many patients presenting with STEMI (Keeley et al., 2003). These benefits however are 
only sustained within 2 to 3 hours of door-to-balloon times (Levine et al., 2011). Given 
the current context, a rural urban setting without PCI capable facilities, the recommended 
target d2b times of less than 120 minutes are often a difficult feat to achieve. One of the 
greatest barriers to achieving target time is the inter-hospital transfer process (Scheller et 
al., 2003). This process can significantly increase times to treatment. This can be due to 
certain factors including; unsafe weather conditions for the air ambulance transfer, a lack 
of beds at the tertiary receiving centre as well a numerous other health care resource 
limitations which indirectly can affect transfer times. Therefore the current review of the 
literature will focus specifically on the results of randomized trials comparing fibrinolysis 
with transfer to another hospital for PCI and outcomes associated with facilitated or 
rescue PCI.
Facilitated PCI-use with fibrinolytics versus PCI alone
A study conducted by Widimisky et al. (2000), referred to as the PRAGUE study 
(Primary Angioplasty in patients transferred from General community hospitals to 
specialized PTCA Units with or without Emergency thrombolysis) compared three 
different reperfusion strategies in patients with AMI, presenting within six horns of
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symptom onset at community hospitals without a catheterization laboratory and related 
PCI capabilities. Patients were randomized into one of the three treatment groups namely; 
group A (thrombolytic therapy in community hospitals (n=99)), group B  (thrombolytic 
therapy during transportation to angioplasty (n=100)), and group C (immediate 
transportation for primary angioplasty without pre-treatment with thrombolysis (n=101)). 
The transport distance to the specialized PCTA units varied between 5 and 74 kilometers. 
There were no complications during transportation in group C. However, complications 
occurred during transfer for group B involving two instances of ventricular fibrillation. 
Median admission-reperfusion time in transported patients was as follows; group B 106 
minutes and group C 96 minutes. These times compared favorably with the anticipated 90 
minutes time in group A. The combined primary end-point, death or reinfarction and/or 
stroke at 30 days, was less frequent in group C (8%) compared to both groups B (15%) 
and A (23%, p < 0.02). The incidence of reinfarction was markedly reduced by transport 
to primary angioplasty (1% in group C vs 7% in group B vs 10% in group A, p < 0.03). 
Therefore, Widimisky and collegues (2000) concluded that transferring patients from 
community hospitals to a tertiary angioplasty centre, in the acute phase of myocardial 
infarction, was both feasible and safe. Furthermore this strategy was found to be 
associated with a significant reduction in the incidence of reinfarction and the combined 
clinical end-point of death, reinfarction, and stroke at 30 days (group C 8% and group B 
15%) when compared to standard thrombolytic therapy at the community hospital (23%,
p < 0. 02).
Three years later there was a follow-up study conducted to the PRAGUE trial, 
entitled the PRAGUE-2 trial by Widimisky et al. (2003). The PRAGUE-2 study involved
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the randomization of 850 patients with acute ST elevation myocardial infarction 
presenting within 12 hours to the nearest community hospital without a catheter 
laboratory to either thrombolysis in this hospital (TL group, n=421) or immediate 
transport for primary percutaneous coronary intervention (PCI group, n=429). The 
primary end-point was defined as 30-day mortality while the two secondary end-points 
included; death, reinfarction, and /or stroke at 30 days, a combined end-point, and 30-day 
mortality among patients treated within 0-3 hours and 3-12 hours after symptom onset. 
The maximum transport distance to catheter laboratories was 120 kilometres. There were 
five unspecified complications (1.2%) that occurred during patient transport. 
Randomization-balloon time in the PCI group was between 70 and 124 minutes, and 
randomization-needle time in the TL group was between 2 to 22 minutes. Mortality at 30 
days was 10.0% in the TL group compared to 6.8% mortality in the PCI group (p = 0.12, 
intention-to-treat analysis). Mortality of 380 patients who actually underwent PCI was 
6.0% versus 10.4% mortality in 424 patients who finally received thrombolysis, TL 
group (p < 0.05). Among the 299 patients randomized more than 3 hours after the onset 
of symptoms, the mortality of the TL group reached 15.3% compared to 6% in the PCI 
group (p < 0.02). Patients randomized within 3 hours of symptom onset (n=551) had no 
difference in mortality whether treated by TL (7.4%) or transferred to PCI (7.3%). A 
combined end-point occurred in 15.2% of the TL group versus 8.4% of the PCI group (p 
< 0.003). Widimisky et al. (2003) thus concluded that long distance transport from a 
community hospital to a tertiary PCI centre in the acute phase of AMI is safe as this 
strategy was associated with marked decreases in mortality in patients presenting more 
than 3 hours after symptom onset. However for patients presenting within 3 hours of
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symptom onset, TL results were similar to the results in long distance transport for PCI.
The Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events 
(FINESSE) study by Ellis et al. (2004) was a prospective, multicenter, randomized, 
double-blind, placebo-controlled trials involving 3000-patients. The study compared the 
efficacy and safety of early administration of reduced-dose reteplase and abciximab 
combination therapy or abciximab alone followed by PCI with abciximab alone 
administered just before PCI for AMI. Patients were randomized to one of these two 
facilitated PCI treatments, reduced-dose reteplase and abciximab combination therapy or 
abciximab alone followed by PCI with abciximab alone, or primary PCI in a 1:1:1 
fashion. The primary end point was the composite of all-cause mortality or post-MI 
complications within 90 days of randomization. The primary safety outcome assessment 
was made through the use of the Thrombolysis In Myocardial Infarction (TIMI) score for 
the outcome of major bleeding. One-year mortalities in the three groups, reduced-dose 
reteplase and abciximab combination therapy or abciximab alone followed by PCI with 
abciximab alone, or primary PCI, were 6.3%, 7.4%, and 7.0%, respectively (p = NS), 
representing 1.1%, 1.9%, and 2.5% increments since the 90-day outcome (p = 0.053 for 
combination treatment vs. primary PCI). A favorable trend with combination treatment 
was seen for patients with anterior MI (p = 0.09), but no other specified groups were 
shown to benefit. Independent baseline correlates of 1 -year mortality were systolic blood 
pressure less than 100 mm Hg, prior myocardial infarction, age, Killip class greater than 
1, anterior MI, body mass index less than or equal to 25 kg/m2, heart rate greater than 100 
beats/min, and no statin use. Based on the results Ellis et al. (2004) concluded that 
widespread utilization of the facilitated approaches tested could not be justified, but that
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high-risk patient groups such as patients with anterior MI deserve further study.
The GRACIA-2 trial (2007) was a randomized controlled trial that evaluated 
whether lytic-based early routine angioplasty represents a reasonable reperfusion option 
for victims of STEMI irrespective of geographic or logistical barriers, more specifically 
in cases where PPCI was not possible within the recommended guideline times. The trial 
involved a total o f 212 AMI STEMI patients which were randomized to either the full 
tenecteplase followed by stenting within 3-12 hours of randomization (early routine post­
fibrinolysis angioplasty; n=104), or to undergo primary stenting with abciximab within 3 
hours of randomization (primary angioplasty; n=108). The primary endpoints were 
defined as epicardial and myocardial reperfusion, and the extent of left ventricular 
myocardial damage, determined by means of the infarct size and six-week left ventricular 
function. The secondary endpoints were defined as the acute incidence of bleeding and 
the six-month composite incidence of death, reinfarction, stroke, or revascularization. 
Results indicated that early routine post-fibrinolysis angioplasty resulted in higher 
frequency (21 versus 6%, p = 0.003) of complete epicardial and myocardial reperfusion 
(TIM I3 epicardial flow and TIMI 3 myocardial perfusion and resolution of the initial 
sum of ST-segment elevation > or = 70%) following angioplasty. Both groups were 
similar regarding infarct size (area under the curve of CK-MB: 4613 +/- 3373 versus 
4649 +/- 3632 microg/L/h, p= 0.94); 6-week left ventricular function (ejection fraction: 
59.0 +/- 11.6 versus 56.2 +/- 13.2%, p= 0.11; end systolic volume index: 27.2 +/- 12.8 
versus 29.7 +/-13.6, p = 0.21); major bleeding (1.9 versus 2.8%, p = 0.99) and six month 
cumulative incidence of the clinical endpoint (10 versus 12%, p = 0.57; relative risk:
0.80; 95% Cl: 0.37-1.74). Thus Fernandez-Aviles et al. (2007) concluded that early
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routine post-fibrinolysis angioplasty safely results in better myocardial perfusion than 
primary angioplasty as despite its delayed application, this approach was seen to be 
equivalent to primary angioplasty in limiting infarct size and preserving left ventricular 
function.
Transfer for PPCI vs. Immediate thrombolysis in AMI
The AIR-PAMI study by Grines et al. (2002) involved high-risk AMI patients 
(aged 70 years or older, anterior MI, Killip class II/III, heart rate greater than 100 
beats/min or systolic blood pressure less than 100 mm Hg) who were eligible for 
thrombolytic therapy. Patients (n= 138) were randomized to either of two treatment arms, 
transfer for primary PTCA (n=71) or on-site thrombolysis (n=67). The time from arrival 
to treatment was delayed in the transfer group (155 versus 51 min, p< 0.0001), largely 
due to the initiation o f transfer (43 min) and transport time (26 min). Patients randomized 
to transfer had a reduced hospital stay (6.1 +/- 4.3 versus 7.5 +/- 4.3 days, p= 0.015) and 
less ischemia (12.7% versus 31.8%, p = 0.007). At 30 days, a 38% reduction in major 
adverse cardiac events was observed for the transfer group however, because of the 
inability to recruit the necessary sample size, this did not achieve statistical significance 
(8.4% versus 13.6%, p = 0.331). Grines et al. (2002) concluded that high-risk patients 
with AMI at hospitals without a catheterization laboratory may have an improved 
outcome when transferred for primary PTCA versus on-site thrombolysis and suggested 
that the marked delay in the transfer process suggests a role for triaging patients directly 
to specialized heart-attack centers.
The DANAMI-2 (2003) trial randomly assigned 1572 patients with AMI to 
treatment with angioplasty or accelerated treatment with intravenous alteplase; 1129
30
patients were enrolled at 24 referral hospitals and 443 patients at five invasive-treatment 
centers. The primary study end point was a composite of death, clinical evidence of 
reinfarction, or disabling stroke at 30 days. Among patients who underwent 
randomization at referral hospitals, the primary end point was reached in 8.5% of the 
patients in the angioplasty group, as compared with 14.2% of those in the fibrinolysis 
group (p=0.002). The results were similar among patients who were enrolled at invasive- 
treatment centers: 6.7% of the patients in the angioplasty group reached the primary end 
point, as compared with 12.3% in the fibrinolysis group (p=0.05). Among all patients, the 
better outcome after angioplasty was driven primarily by a reduction in the rate of 
reinfarction (1.6% in the angioplasty group versus. 6.3% in the fibrinolysis group, 
p<0.001); no significant differences were observed in the rate of death (6.6 % versus 7.8 
%, p-0.35) or the rate of stroke (1.1 % versus 2.0 %, p=0.15). Ninety-six % of patients 
were transferred from referral hospitals to an invasive-treatment center within two hours. 
Andersen et al. (2003) concluded that a strategy for reperfusion involving the transfer of 
patients to an invasive-treatment center for primary angioplasty is superior to on-site 
fibrinolysis, provided that the transfer takes two hours or less.
The ASSENT-4 trial (2006) investigated whether the administration of full-dose 
tenecteplase before a delayed PCI could mitigate the negative effect of this delay. 
ASSENT-4 was a randomized study in which patients with STEMI of less than six hours 
in duration were (scheduled to undergo primary PCI with an anticipated delay of 1-3 
hours) to standard PCI (n=838) or PCI preceded by administration of full-dose 
tenecteplase (n=829). All patients received aspirin and a bolus, without an infusion, of 
unfractionated heparin. The primary endpoint was death or congestive heart failure or
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shock within 90 days.
It is important to note that the initial plan was to enroll 4000 patients, but the 
premature cessation of enrollment was recommended by the data and safety monitoring 
board because of a higher in-hospital mortality in the facilitated than in the standard PCI 
group (6% [43 of 664] versus 3% [22 of 656], p=0.0105). Of those enrolled, six were lost 
to follow-up in the facilitated PCI group and seven in the other group. Median time from 
randomization to first balloon inflation was similar in both groups. The median time from 
bolus tenecteplase to first balloon inflation was 104 min. The primary endpoint was 19% 
(151 of 810) of patients assigned facilitated PCI versus 13% (110 of 819) in those 
randomized to primary PCI (relative risk (RR): 1.39, 95% Cl 1.11 -1.74; p=0.0045). It 
was also found that during the hospital stay, significantly more strokes (1.8% (15 of 829) 
versus 0, p<0.0001), but not major non-cerebral bleeding complications (6% (46 of 829) 
versus 4% [37 of 838], p=0.3118), were reported in patients assigned facilitated rather 
than standard PCI. Furthermore more ischemic cardiac complications, such as 
reinfarction (6% (49 o f 805) versus 4% (30 of 820), p=0.0279) or repeat target vessel 
revascularization (7% (53 of 805) versus 3% (28 of 818), p=0.0041) within 90 days in 
this study group. Van der Werf et al. (2006) concluded that the strategy of full-dose 
tenecteplase with antithrombotic co-therapy, as used in this study and preceding PCI by 
one to three hours, was associated with more major adverse events than PCI alone in 
STEMI and cannot be recommended.
A follow-up study to the DANAMI-2 trial was conducted by Nielsen et al. in 
2010. The study involved the randomization of 1572 patients with STEMI to primary 
angioplasty or intravenous alteplase; 1129 patients were enrolled at 24 referral hospitals
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and 443 patients at five angioplasty centres. Ninety-six percent of inter-hospital transfers 
for angioplasty were completed within two hours and no patients were lost to follow-up. 
The composite endpoints primarily, death, clinical re-infarction, or disabling stroke, were 
reduced by angioplasty when compared with fibrinolysis at 3 years (19.6% versus 25.2%, 
p= 0.006). For patients transferred to angioplasty compared with those receiving on-site 
fibrinolysis, the composite endpoint occurred in 20.1% versus 26.7% (p= 0.007), death in 
13.6 versus 16.4% (p= 0.18), clinical re-infarction in 8.9% versus 12.3% (p= 0.05), and 
disabling stroke in 3.2% versus 4.7% (p= 0.23). The benefit of transfer for primary 
angioplasty based on the composite endpoint was sustained after three years. Nielsen et 
al. (2010) concluded that for patients with characteristics such as those in DANAMI-2, 
primary angioplasty should be the preferred treatment strategy provided that inter­
hospital transfer can be completed within two hours.
The LIPSIA-STEMI (2011) multicenter trial sought to assess the merits of 
facilitated percutaneous coronary intervention (PCI) versus primary PCI in an ST- 
segment elevation myocardial infarction (STEMI) network with long transfer distances in 
patients presenting early after symptom onset. Patients with STEMI presenting less than 
3 hours after symptom onset, were randomized to either pre-hospital-initiated facilitated 
PCI using tenecteplase (Group A; n = 81) or primary PCI (Group B; n = 81) plus optimal 
antithrombotic co-medication. The primary endpoint was infarct size assessed by 
delayed-enhancement magnetic resonance imaging. Secondary endpoints included 
micro vascular obstruction and myocardial salvage, early ST-segment resolution, and a 
composite of death, repeated myocardial infarctions, and congestive heart failure within 
30 days. The median time from symptom onset to randomization was 64 min
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(interquartile range (IQR): 42 to 103 min) in Group A versus 55 min in Group B (IQR: 
27 to 91 min; p = 0.26). Despite better pre-interventional TIMI (Thrombolysis In 
Myocardial Infarction) flow in Group A (71% versus 35% TIMI flow grade 2 or 3; p < 
0.001), the infarct size tended to be worse in Group A versus Group B (17.9% of left 
ventricle IQR: 8.4% to 35.0%) versus 13.7% IQR: 7.5% to 24.0%); p = 0.10). There was 
also a strong trend toward more early and late microvascular obstruction, (p = 0.06 and 
0.09) and no difference in ST-segment resolution (p = 0.26). The combined clinical 
endpoint showed a trend toward higher event rates in Group A (19.8% versus 13.6%; p = 
0.13, relative risk (RR): 0.52,95% Cl: 0.23 to 1.18). Thiele et al. (2011) concluded that 
in STEMI patients presenting early after symptom onset with relatively long transfer 
times, a fibrinolytic-based facilitated PCI approach with optimal antiplatelet co­
medication does not offer a benefit over primary PCI with respect to infarct size and 
tissue perfusion.
Early PCI when PPCI is not feasible
The Southwest German Interventional Study in Acute Myocardial Infarction 
(SIAM-III trial) (2003) investigated potentially beneficial effects of immediate stenting 
after thrombolysis as opposed to a more conservative treatment regimen. The SIAM III 
study was a multicenter, randomized, prospective, controlled trial in patients receiving 
thrombolysis in AMI (less thanl2 hours). Patients of group I were transferred within six 
hours after thrombolysis for coronary angiography, including stenting o f the IRA. Group 
II received elective coronary angiography two weeks after thrombolysis with stenting of 
the IRA. A total of 197 patients were randomized, 163 patients fulfilled the secondary 
(angiographic) inclusion criteria (82 in group I, 81 in group II). Immediate stenting was
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associated with a significant reduction of the combined end point after six months 
(ischemic events, death, reinfarction, target lesion revascularization 25.6% versus 50.6%, 
p = 0.001). Bohmer et al. (2003) concluded that immediate stenting after thrombolysis 
leads to a significant reduction of cardiac events compared with a more conservative 
approach including delayed stenting after two weeks.
The GRACIA-1 trial (2004) was designed to reassess the benefits of an early 
post-thrombolysis interventional approach in the era of stents and new antiplatelet agents. 
The study involved 500 patients with thrombolysed STEMI, with recombinant tissue 
plasminogen activator. Patients were randomly assigned to angiography and intervention 
if indicated within 24 hours of thrombolysis, or to an ischaemia-guided conservative 
approach. The primary endpoint was the combined rate of death, reinfarction, or 
revascularisation at 12 months. Invasive treatment included stenting of the culprit artery 
in 80% (199 of 248) patients, bypass surgery in six (2%), non-culprit artery stenting in 
three, and no intervention in 40 (16%). Pre-discharge revascularisation was needed in 51 
of 252 patients in the conservative group. By comparison with patients receiving 
conservative treatment, by 1 year, patients in the invasive group had lower frequency of 
primary endpoint (23 (9%) versus 51 (21%), relative risk 0.44 (95% Cl 0.28-0.70), 
p=0.0008), and they tended to have reduced rate of death or reinfarction (7% versus 12%, 
0.59 (0.33-1.05), p=0.07). Index time in hospital was shorter in the invasive group, with 
no differences in major bleeding or vascular complications. At 30 days both groups had a 
similar incidence of cardiac events. In-hospital incidence of revascularisation induced by 
spontaneous recurrence o f ischaemia was higher in patients in the conservative group 
than in those in the invasive group. Fernandez-Aviles et al. (2004) concluded that in
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patients with STEMI, early post-thrombolysis catheterization and appropriate 
intervention is safe and might be preferable to a conservative strategy since it reduces the 
need for unplanned in-hospital revascularization, and improves 1-year clinical outcomes.
The CARESS-in-AMI trial (2008) involved the randomization of patients with 
STEMI treated by thrombolysis and abciximab at a non-interventional hospital to 
immediate transfer for PCI, or to standard medical therapy with transfer for rescue 
angioplasty. 600 patients aged 75 years or younger with one or more high-risk features 
including; extensive ST-segment elevation, new-onset left bundle branch block, previous 
myocardial infarction, Killip classification of greater than two, or left ventricular ejection 
fraction < or =35%) in various hospitals in France, Italy, and Poland were treated with 
half-dose reteplase, abciximab, heparin, and aspirin, and randomly assigned to immediate 
transfer to the nearest interventional centre for PCI, or to management in the local 
hospital with transfer only in case of persistent ST-segment elevation or clinical 
deterioration. The primary endpoint was a composite of death, reinfarction, or refractory 
ischaemia at 30 days. Of the 299 patients assigned to immediate PCI, 289 (97.0%) 
underwent angiography, and 255 (85.6%) received PCI. Rescue PCI was done in 91 
patients (30.3%) in the standard care/rescue PCI group. The primary outcome occurred in 
13 patients (4.4%) in the immediate PCI group compared with 32 (10.7%) in the standard 
care/rescue PCI group (hazard ratio 0.40; 95% Cl: 0.21-0.76, p=0.004). Major bleeding 
was seen in ten patients in the immediate group and seven in the standard care/rescue 
group (3.4% versus 2.3%, p=0.47). Strokes occurred in two patients in the immediate 
group and four in the standard care/rescue group (0.7% versus 1.3%, p=0.50). Di Mario 
et al. (2008) concluded that immediate transfer for PCI improves outcome in high-risk
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patients with STEMI treated at a non-interventional centre with half-dose reteplase and 
abciximab.
The NORDISTEMI trial (2007) was done to compare a strategy of immediate 
transfer for percutaneous coronary intervention (PCI) with an ischemia-guided approach 
after thrombolysis in patients with very long transfer distances to PCI. A total of 266 
patients with acute STEMI living in rural areas with more than 90-min transfer delays to 
PCI were treated with tenecteplase, aspirin, enoxaparin, and clopidogrel and randomized 
to immediate transfer for PCI or to standard management in the local hospitals with early 
transfer, only if indicated for rescue or clinical deterioration. The primary endpoint was a 
composite of death, reinfarction, stroke, or new ischemia at 12 months. The primary 
endpoint was reached in 28 patients (21%) in the early invasive group compared with 36 
(27%) in the conservative group (hazard ratio: 0.72,95% Cl: 0.44 to 1.18, p = 0.19). The 
composite of death, reinfarction, or stroke at 12 months was significantly reduced in the 
early invasive compared with the conservative group (6% versus 16%, hazard ratio: 0.36, 
95% Cl: 0.16 to 0.81, p = 0.01). No significant differences in bleeding or infarct size 
were observed. Bohmer et al. (2007) thus concluded that immediate transfer for PCI did 
not improve the primary outcome significantly, but reduced the rate o f death, 
reinfarction, or stroke at 12 months in patients with STEMI, treated with thrombolysis 
and clopidogrel in areas with long transfer distances.
The TRANSFER-AMI trial was conducted by Cantor et al. (2009) to determine 
the role and optimal timing of routine PCI after fibrinolysis. 1059 high-risk patients who 
had a myocardial infarction with ST-segment elevation and who were receiving 
fibrinolytic therapy at centers that did not have the capability of performing PCI were
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randomly assigned to either standard treatment (including rescue PCI, if required, or 
delayed angiography) or a strategy of immediate transfer to another hospital and PCI 
within six hours after fibrinolysis. All patients received aspirin, tenecteplase, and heparin 
or enoxaparin; and concomitant clopidogrel was recommended. The primary end point 
was the composite of death, reinfarction, recurrent ischemia, new or worsening 
congestive heart failure, or cardiogenic shock within 30 days.
Cardiac catheterization was performed in 88.7% of the patients assigned to 
standard treatment a median of 32.5 hours after randomization and in 98.5% of the 
patients assigned to routine early PCI a median of 2.8 hours after randomization. At 30 
days, the primary end point occurred in 11.0% of the patients who were assigned to 
routine early PCI and in 17.2% of the patients assigned to standard treatment (relative 
risk with early PCI, 0.64; 95% Cl: 0.47 to 0.87; p=0.004). There were no significant 
differences between the groups in the incidence of major bleeding. Among high-risk 
patients who had a myocardial infarction with ST-segment elevation and who were 
treated with fibrinolysis, transfer for PCI within six hours after fibrinolysis was 
associated with significantly fewer ischemic complications than was standard treatment. 
Thus Cantor et al. (2009) concluded that transfer for PCI among high-risk STEMI 
patients is most effective provided the transfer occurs within six hours of fibrinolyctic 
treatment.
A real-world perspective
Some of the above listed clinical trials have documented that use of “facilitated” 
percutaneous coronary intervention (PCI) in patients with ST-segment elevation 
myocardial infarction (STEMI) may be harmful. McKay et al. (2009) examined in­
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hospital outcomes in 1,553 consecutive patients with STEMI without cardiogenic shock 
who underwent PCI at a single tertiary center within six hours of presentation were 
analyzed. The study group included 767 patients who underwent primary PCI who 
initially presented to the tertiary center and were triaged for emergent PCI and 786 
patients who underwent facilitated PCI who were pretreated at a community hospital with 
a glycoprotein Ilb/IIIa platelet inhibitor and/or intravenous thrombolytic therapy before 
transfer for catheter-based therapy. Compared with patients who underwent primary PCI, 
the facilitated PCI group had longer door-to-balloon times (162 +1-51 versus 113 +/-61 
minutes), higher baseline infarct-vessel TIM I3 flow rates (52.8% versus 25.4%; p 
<0.001), and no increase in major adverse in-hospital outcomes. In patients treated with 
door-to-balloon times greater than 90 and less than 150 minutes, patients who underwent 
facilitated PCI had fewer composite major adverse clinical events (combined mortality, 
recurrent myocardial infarction, emergent repeated PCI, hemorrhagic and non- 
hemorrhagic stroke, and non-intracranial TIMI major bleeding) compared with patients 
who underwent primary PCI (RR 0.50, 95% Cl 0.26 to 0.96, p=0.034). McKay etl al. 
(2009) concluded that facilitated PCI can be safely used to increase pharmacologic 
reperfusion before catheter-based therapy in patients with STEMI without an increase in 
clinical hazard and with fewer major adverse clinical events in patients treated with door- 
to-balloon times greater than 90 and less than 150 minutes.
Overall the evidence from the literature suggests that PCI has the potential to 
significantly reduce morbidity and mortality post ACS provided the access occurs in a 
timely fashion (Di Mario et al., 2008; McKay et al. 2009). When compared to 
thrombolysis, primary PCI is considered to be the more effective strategy in reducing
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rates of re-infarction and stroke (Bohmer et al., 2003). This being said, transfer for 
primary PCI was seen as an effective intervention provided the transfer time was within 2 
hours after thrombolytic therapy (Grines et al., 2002; Andersen et al., 2003; Nielsen et al., 
2010). However thrombolysis still remains the treatment of choice in ST-segment 
elevation myocardial infarction (STEMI) when primary PCI cannot be performed within 
90 to 120 min (Levine et al., 2011). In some cases where primary PCI is not possible, or 
thrombolysis has failed, rescue or facilitated PCI is the next best option and timely access 
to these interventions is associated with improved patient outcomes such as lower risk of 
death, re-infarction, hospital re-admission rates and recurrent ER visits (Bohmer 2003; 
Fernandez-Aviles et al. 2004; Cantor et al., 2009).
GRACE risk stratification tool
There are a number of risk stratification tools used in emergency departments 
around the world for triaging, referring and decision-making purposes when it comes to 
resource allocation including the TIMI score, NERS, SYNTAX and GRACE score. The 
Global Registry of Acute Coronary Events (GRACE) score one of the more widely used 
and well-documented scores in the use of predicting both in-hospital and at discharge to 
six months mortality for patients who have experienced ACS. The GRACE risk 
stratification tool was used to determine which STEMI and NSTEMI/UA patients are at 
highest-risk for mortality upon admission and should be referred for and receive 
angiography and PCI services the fastest (Appendix F). It was used instead of the more 
commonly used TIMI score at UHNBC as variables for GRACE score calculation are 
better documented on patient files and because the GRACE risk score does not require 
information on the patient’s aspirin use, which can often be misreported or missing from
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charts. The score can be calculated for all ACS patients using the following information 
that can be found in their respective medical records including: patient age; heart rate 
(HR); systolic blood pressure (SBP); creatine levels; CHF (Congestive Heart Failure 
Classification); cardiac arrest at admission; ST-segment deviation; elevated cardiac 
enzymes/markers (specifically troponin).
Risk stratification of patients using the GRACE risk score
The Global Registry of Acute Coronary Event (GRACE) risk score was 
developed in a large multinational registry to predict in-hospital mortality across the 
broad spectrum of acute coronary syndromes (ACS). The GRACE risk score will be used 
to determine which STEMI and NSTEMI/UA patients are at highest-risk upon admission 
and therefore should theoretically be referred for and receive angiography and PCI the 
fastest. While it is one of many risk stratification tools for ACS available in today’s 
market, the GRACE risk score has been accepted as a fast and valid method to assess a 
patient’s cardiovascular risk and can be used in complement to clinical evaluation to help 
guide patient care due to the simplicity in calculation (Tang et al., 2007; Fox et al., 2006). 
Current ACC/AHA guidelines promote the use of either TIMI or GRACE risk scores for 
the risk stratification of ACS patients (Wright et al., 2011).
Validation of the use of GRACE to risk-stratify ACS patients
The Global Registry of Acute Coronary Events (GRACE) was established in 1999 
with the purpose of resolving major uncertainties into what ACS is comprised of, 
defining the treatment of ACS patients, and to aid in the characterizing of outcomes for
41
ACS patients (Fox et al., 2010). The GRACE risk models have been derived and 
validated in large unselected cohorts of patients worldwide. These models have been 
tested and have shown to be valid for all forms of ACS, including STEMI, NSTEMI and 
UA (Alter et al., 2006; de Araujo et al., 2005; Bradshaw et al., 2006; Gale et al., 2009; 
Tang et al., 2007; Yan et al., 2004; Yan et al., 2007). The use of GRACE risk models is 
widespread and their usefulness in providing modem day cardiac care is echoed through 
guidelines put forth by the European Society o f Cardiology (Bassand et al., 2007), NICE 
(NICE, 2010) and the ACC/AHA (Kushner et al., 2009).
GRACE vs. other risk scores
Overall, the literature is indicative of the fact that GRACE risk prediction models 
are valid and robust predictors of both in-hospital and six month post hospital discharge 
mortality for all forms of ACS. Some studies have even demonstrated GRACE as an 
effective risk prediction model for long-term mortality of ACS patients for up to five 
years (Kozieradzka et al., 2011). However further studies to validate these findings are 
warranted. For the purposes of the current study, in-hospital and to six month mortality 
prediction models are of particular interest as it is this version which has been most 
widely applied in clinical settings for the purposes of risk estimation for patients with 
ACS (Fox et al., 2006).
Generally speaking, the findings from the literature demonstrate the effectiveness 
and appropriateness of using the GRACE risk score for risk stratification purposes of 
patients with unselected ACS. The GRACE risk score has been well documented in the 
use of predicting mortality rates for patients who have experienced ACS and can be used
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to determine both in-hospital and six months post hospital discharge ACS mortality rates 
(Aragam et al. 2009; Elabrouni et al., 2009; Abu-Assi et al., 2010; Stracke et al., 2010;).
It has been found to have superior prognostic capacity when compared to the 
Thrombolysis in Myocardial Infarction (TIMI) score (Correia et al., 2010, Elbarouni et 
al., 2009, Fox et al., 2006). In addition to this, GRACE risk stratification is seen as being 
more applicable in hospital settings as it can be used for a wider age range of patients in 
comparison to the TIMI risk score (Ramsay et al., 2007) and it does not require there to 
be documentation on a patients use of aspirin (Fox et al., 2006). Furthermore, risk 
stratification using either TIMI or GRACE risk scores has been argued to be superior 
versus electrocardiograms and detection of troponin markers at presentation in the 
prediction of significant coronary events (Ramsay et al., 2007).
Gaps in the literature
There are certain limitations to consider when interpreting these results. These 
studies represent randomized-control trials, which occurred in conditions not always 
reminiscent of the real world. For example, current real world hospital transfer times vary 
greatly and in most cases can more than two fold of those times eluded to in these trials 
(Angeja et al., 2002; Nallamothu et al., 2005).
After extensive searches of the literature it can be said that there have been no 
previous studies conducted on this particular topic from a rural northern perspective. It is 
therefore important to note that this work will serve as a starting point to investigate this 
area of cardiac services in the region of northern British Columbia. Furthermore, current 
practice guidelines for cardiac care are based on those developed by the ACC/AF1A. 
While these guidelines are invaluable in both clinical work and research, it is important to
note that they may not always reflect the realities of a Canadian landscape. The structure 
of the American health care system coupled with the more dense and disperse American 
population has resulted in the existence of more higher-level health care facilities 
including catherization labs than in Canada. What is possible in terms of access to 
services and transfer times in the United States can be at times in stark contrast to that 
Canada due to a number of differences in the national context. This study will aim to 
explore these issues from a northern and rural perspective and provide directions for 
future research as well as recommendations for improvements to current cardiac care for 
patients presenting with ACS at UHNBC.
Summary
There has been much research into the importance of rapid access to PCI, as well 
as the risk stratification of ACS patients using GRACE risk scores. Despite all this 
research, there remains a gap in the literature when it comes to studying these topics from 
a rural point of view. It is a well acknowledged fact that patients living in rural settings 
face unique health care challenges. These challenges can be in the form of poorer health 
status and health outcomes or limitations in access to health care services. Addressing the 
aforementioned research aims from a rural standpoint will offer a relevant perspective to 
the issues faced by those with acute coronary syndrome in a rural health care setting.
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CHAPTER THREE: METHODS
This chapter provides an outline of the methods employed in the study. A 
retrospective approach was used. A medical records chart review was conducted to obtain 
patient data of interest. The use of PowerChart, a computer database for patient medical 
information, was used to locate any missing data points and validate the data collected 
from patient charts.
Study Design
This is a population-based study encompassing a retrospective analysis of all ACS 
admissions to the UHNBC emergency department was performed. Descriptive statistics 
on selected patient data were used to determine; patient baseline characteristics, patient 
residence, classification of ACS cases, average length of hospital stay, average length of 
hospital stay prior to transfer, and classification of patients given thrombolytics by 
diagnosis. GRACE risk scores for admission to in-hospital and admission to six months 
probability of death or re-infarction were also calculated.
In the current study, rescue or facilitated PCI was of most interest considering that 
UHNBC lacks a catherization lab to perform PCI and patients requiring the procedure 
need to be sent to one of the five provincial catherization labs to receive it. This study 
was a retrospective review of medical records o f patients presenting to UHNBC with 
ACS from January through to December of 2012. Medical records were obtained through 
the medical records department at UHNBC.
A medical record can be defined as a document containing patient focused 
medical information (Worster et al., 2004). There are currently no universally accepted
45
standards for reporting or conducting medical record reviews (Gilbert et al., 1996). 
Medical records hold information for the purpose of documenting a patient encounter 
with the medical system and patient data are typically not collected for research purposes. 
In fact medical records have certain important limitations when it comes to using them as 
data collection including; data not being recorded for research purposes, and the 
possibility of having missing or incomplete information.
Despite these shortcomings medical record review studies are an appropriate 
method for many situations and can be used for pilot studies, to inform prospective 
clinical trials, to determine disease patterns throughout extended periods of time and to 
investigate questions difficult to answer in prospective trials (Gilbert et al., 1996; Lemer 
et al., 2002; Worster et al., 2004). Today medical record review studies comprise over 
25% of all scientific studies published in peer reviewed emergency medical journals and 
are used for data collection in 53% of emergency medical services studies (Worster & 
Haines, 2004). While there are limitations to using medical records for research purposes 
the importance and value of medical record reviews in emergency medical research 
cannot be underestimated. They provide a valuable and rich source of patient derived 
medical information which often cannot be found in other environments or captured 
through typical methods of data collection in research such as surveys or patient based 
reporting (Dunn et al., 2006). Furthermore, the information is documented by 
professionals in the medical field, making the data less prone to patient recall and 
reporting bias (Worster & Haines, 2004).
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Study Population
The study population consisted of patients who presented to UHNBC with ACS 
during January 2012 through to December 2012. A total of 265 cases were identified. 
These cases represented 249 people as 16 patients presented to the emergency department 
more than once throughout the calendar year.
Community Profile
A community profile for Prince George was extracted from the 2011 census data 
and the community health information portal through Northern Health (Statistics Canada, 
2012; Northern Health Community Health Information Portal, 2013). The profile of this 
community is discussed based on demographic characteristics, health status and health 
facilities in this community. The population for the city of Prince George was found to be 
approximately 84,232. The mean age of the population was 39.0 years. The annual 
number of births for women of childbearing age was 1,045. The annual death rate was 
574. The average life expectancy was 79.3 years, lower than the provincial average of 82 
years.
Data source and extrapolation
Medical records were obtained through the medical records department at 
UHNBC. A request for access to records was put in to the department requesting access 
to the records o f those patients presenting to the emergency department of UHNBC with 
ACS from January 2012 through to December 2012. The patient charts were pulled by 
the medical records department staff.
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Patient data was initially entered into an extraction sheet in an Excel workbook by 
the month of presentation to the emergency department. All variables, including 
demographic and lab-based values were determined from the patient visit to the 
emergency department for ACS. For example, there was no looking through past records 
of patient encounters to determine any variables whether missing or otherwise. This 
information was located though the initial admission paperwork, ambulance summary, 
hospital discharge form, hospital transfer summary, cardiac catherization lab referral 
form, physician notes, nurses notes, PharmaNet medication history, and lab reports. 
Patients were given a unique identifier different from their personal health number to 
protect their identity.
The variables extracted from the chart included: date and time of admission, area 
of residence, mode of arrival, triage code, sex, age, height, weight, heart rate (bpm), 
blood pressure, creatine, glomerular filtration rate (gif), CHF Killip classification, 
whether there was a cardiac arrest at admission, whether there was ST-segment elevation, 
whether there was elevation of cardiac enzymes, whether the patients received 
thrombolysis, diagnosis, date and time of discharge (whether for transfer or otherwise), 
facility transfer or discharged to, procedure and previous cardiac history including the 
presence of risk factors for cardiovascular disease. From these variables there were a 
number of data points calculated including: total length of hospital stay regardless of 
discharge status was calculated, patient body mass index using the documented height 
and weight of patients who had these data points in their charts and GRACE risk scores.
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Data collection and criterion
Data were collected for patients for the calendar year of 2012. The rationale for 
choosing a one year time period from January 2012 to December 2012, was that this 
reflected the most current and available data as well as provided a longer-term picture of 
the situation compared to a shorter time period. This was done to minimize the effect of 
confounding variables that may delay the patient transfer process. Such confounding 
variables may include: differences in seasonal patterns, and health care service levels. 
Data were collected through review of medical charts. Any missing data points of interest 
were located through PowerChart. A total of 344 cases were identified and of these 344 
cases, 265 were found to fit the inclusion/exclusion criteria.
Patients were included in the dataset if  they presented to the UHNBC ED with 
ACS and were found to have true ACS (UA, NSTEMI or STEMI). They were included:
• regardless of their hometown/origin
• each time they presented to the UHNBC ED in the year (i.e one time in 
May of 2012, another in July 2012 and so forth)
• if  they presented directly to the UHNBC ED without being at another 
NHA facility
• if  they were transferred from another NHA facility to UHNBC and the 
referral for the catherization lab was made at UHNBC
• if they were found to have a late-presenting STEMI regardless of whether 
they required transfer to the catherization lab
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Patients were excluded from the dataset if any of the following was true:
• patient was admitted in 2011 but was transferred in 2012 (i.e admitted in 
Dec of 2011 and transferred in Jan 2012)
• patient was admitted in 2012 but was transferred in 2013 (i.e admitted in 
Dec of 2012 and transferred in Jan 2013)
• patient presented to the UHNBC ED as an inpatient (inpatient transfers are 
not captured in the same way as outpatient as vitals and stats are not taken 
upon presentation)
• patients coming to UHNBC from another NHA facility for further 
evaluation (referral for PCI has already been made and tracking would be 
done at the respective hospital of origin)
• patients coming to UHNBC awaiting transfer to the catherization lab 
(referral for PCI has already been made and tracking would be done at the 
respective hospital of origin)
• patient presented to ED and was coded as ACS initially but was found to 
not be true ACS (i.e had elevated blood pressure, exacerbation of COPD)
• patient presented to ED with ACS complaint but left against medical 
advice (AMA) before investigations were completed
Measures and analytic procedures
Once it was determined that the data collection in the Excel workbook was 
complete, data were coded for use in IBM SPSS version 21.0. Dichotomous variables for 
cardiac enzyme elevation, for example, were coded as one for yes and two for no. Males
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were coded as a one and females as a two. All nominal variables such as age or heart rate 
were coded as exact values. Baseline characteristics for the study population were 
determined. They included; age, gender, height, weight, area of residence, and risk 
factors as documented in their respective medical records (smoking history/status, family 
history of CVD, hypertension, diabetes, dyslipidemia, obesity, age, and prior 
cardiovascular history). Body Mass Indexes (BMIs) for patients were also calculated for 
those with both height and weight documented in their charts (Table 1.).
Study patients were divided into three groups according to the diagnostic and 
referral methods. Group 1 comprised of patients presenting with UA. Group 2 consisted 
of patients presenting with either NSTEMI. Group 3 consisted of patients presenting with 
STEMI. Baseline characteristics were determined through descriptive statistics. Analysis 
through crosstabs and one-way analysis of variance (ANOVAs) were conducted to 
determine time to PCI differences between patients presenting with STEMI compared to 
those with NSTEMI or UA. Data analysis was conducted using multivariate logistical 
regression through IBM SPSS version 21.0.
Risk stratification was performed through the use of the GRACE web-based 
calculation tool available through the GRACE website at, http://www.outcomes- 
umassmed.org/grace/acs risk/acs risk content.html. Patient data entered included; 
patient age, heart rate (bpm), systolic blood pressure (mmHg), creatine (umol/L), CHF 
Killip class as per Parakh et al., 2008 (Table 1.), and whether or not the patient had a 
cardiac arrest at admission, ST-segment deviation (as per ECG results), and the presence 
of elevated cardiac enzymes/markers (as per the pathology report) (Table 2.). Risk scores 
were determined and a breakdown of probability of mortality for both admission to in­
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hospital and admission to six months for STEMI and NSTEMI/ UA is provided below 
(Table 3. and Table 4.).
Table 1.
Body Mass Index Classification 
Classification Principal Cutoff Points
Underweight <18.5
Normal 18.5-24.99
Overweight 25.0-29.99
Obese >30.0
Class I 30.0-34.99
Class II 35.0-39.99
Class III >40.0
(Source: Health Canada. Canadian Guidelines for Body Weight Classification in Adults. Ottawa: 
Minister of Public Works and Government Services Canada; 2003.)
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Table 2.
Killip Classification fo r  GRACE
Killip Class Clinical Features
I No evidence of CHF
II Crackles in <50% of lung fields or third heart sound or SBP >90mmHg
III Pulmonary oedema and SBP >90mmHg
IV Cardiogenic shock with crackles, SBP, <90mmHg and evidence of
tissue hypoperfusion
CHF; congestive heart failure
SBP; systolic blood pressure
Table 3.
Troponin Elevation Criteria fo r  GRACE
Value Result
<14 Normal
14-50 Borderline
>50 Positive
>50% from baseline Significant
*Note: these criteria are based on the high-sensitivity troponin scale
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Table 4.
GRACE risk categories fo r  UAfNSTEMl
Risk Category Grace risk score In-hospital Grace risk score To 6 month
(tertile) mortality (%) mortality (%)
Low <108 <1 <88 <3
Intermediate 109-140 1-3 89-118 3-8
High <140 >3 >118 >8
*Note: scores can range from 2-372
(Abu-Assi et al. 2010 and European Society of Cardiology, 2012)
Table 5.
GRACE risk categories fo r  STEMI
Risk Category Grace risk score In-hospital Grace risk score To 6 month
(tertile) mortality (%) mortality (%)
Low <25 <1 27-99 <3
Intermediate 126-154 1-3 100-127 3-8
High <155 >3 >128 >8
*Note: scores can range from 2-372
(Abu-Assi et al. 2010 and European Society of Cardiology, 2012)
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Ethical considerations and confidentiality
The study design and procedures for this study were submitted and were approved 
by both the University o f Northern British Columbia Research Ethics Board (UNBC 
REB) and the Northern Health Research Ethics Board (NH REB) in May of 2013. 
Certificates of ethical approval from both research ethics boards can be found in the 
appendices (Appendix I. and Appendix J.).
Confidentiality of the patient data was strictly maintained throughout all phases of 
the study. Patients were given a unique identifying number unrelated to their Personal 
Health Number (PHN) or Northern Health Encounter Number (NH ENC #) to avoid the 
possibility of patient tracking. All electronic data files were password protected and 
stored on a password-protected computer and the data collected from patient records did 
not contain any identifiable information. The electronic files were further placed in a 
folder that required a username and password for login purposes that only the author of 
this thesis had access to. It was also ensured that the final deliverable, the thesis, did not 
include any patient identifiable information.
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CHAPTER FOUR: RESULTS
This chapter presents the results from the data analyzed for this thesis. A 
descriptive analysis of patient baseline characteristics is provided. Second, statistical 
differences using crosstabs and one-way ANOVAs between patient area of residence, 
classification of cases by diagnosis, and length of hospital stay are presented. This is 
followed by statistical analyses using multiple linear regression of whether longer time to 
PCI was associated with adverse patient outcomes (death, stroke, reinfarction) and 
whether patient time to PCI treatment was correlated with GRACE risk status.
Preliminary data analysis
Preliminary data analyses identified a total of 344 cases. Those not fitting the 
inclusion criteria such as being diagnosed as not having true ACS (i.e. chronic 
obstructive pulmonary disease exacerbation or elevated blood pressure) or being 
inpatients were eliminated. A total of 265 patient cases were identified after the data were 
cleaned and coded. Of these patients 65.6% (n=174) were male, and 34.4% (n=91) were 
female. Ages for the patients ranged from 33 years to 94 years old with the average 
patient age of 64.1 years. The length of stay prior to transfer for the catherization lab 
ranged from 1 day to 47 days with the average length of stay being 4.9 days across all 
diagnostic categories.
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Table 5.
Patient Baseline Characteristics
UA
(n=87)
NSTEMI
(n=113)
STEMI
(n-65)
Median Age (years) 64.0 65.4 61.9
Male (%) 58.6 82.3 80.0
Risk Factors
Age (Males 45+, Females 55+) 90.8 90.3 89.2
Family History 30.0 31.9 29.2
Smoking 33.3 42.5 52.3
Diabetes mellitus 27.6 29.2 21.5
Hypertension 65.5 65.5 46.2
Dyslipidemia 51.7 48.7 36.9
Obesity 40.6 32.7 16.1
Prior Cardiovascular History 48.3 46.0 38.5
MI 20.7 12.4 16.9
CHF 3.5 6.2 6.2
PCI 19.5 19.5 16.9
CABG 18.4 8.9 4.4
Stroke/TIA 3.5 8.9 4.6
AF 2.3 8.0 3.1
PVD 15.0 11.5 4.4
0.949
0.381
*Note: For obesity UA n=32, NSTEMI n=49 and STEMU n=31
MI, myocardial infarction; CHF, congestive heart failure; PCI, percutaneous coronary intervention; 
CABG, coronary artery bypass graft; AF, atrial fibrillation; PVD, peripheral vascular disease
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n=l n=26 n=52 n=33
BMI Class
Figure 4. Classification of patients by body mass index (BMI)
Patients with documented height and weight data in their medical charts (n=l 12) were 
classified according to their BMI. It was found that 0.4% of patients (n=l) were 
underweight (BMI <18.5), 9.8% of patients (n=26) were within normal range (BMI 18.5- 
24.9), 19.6% of patients (n=52) were overweight (BMI 25.0-29.9) and 12.5% of patients 
(n=33) were obese (BMI > 30.0).
Class 2 
n=8
Class of obesity
Figure 5. Classification of obese patients
Patients were classified into classes of obesity if  their BMI was >30.0. There was a total 
of (n=33) 12.5% of patients which were found to be obese (BMI > 30.0). Of the 12.5%, 
7.2% of patients (n=19) were classified as class I obese (BMI 30.0-34.9), 3.0% of patients 
(n=8) were classified as class II obese (BMI 35.0-39.9) and 2.3% of patients (n=6) were 
classified as class III obese (BMI > 40.0).
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Figure 6. Classification of patients by area of residence
Patients (n=265) were classified according to area of residence. Of the 265 patients 81.5% 
(n=216) were Prince George residents. O f the remaining 18.5% of patients (n=49) 57.1% 
of these patients (n=28) were transferred from other hospitals within the Northern Health 
Authority including; Kitimat, Fort St. James, Fort St. John, Valemount, Vanderhoof, 
Bums Lake, Quesnel, Fort Fraser, Mackenzie and Dunster. The remaining 42.9% of 
patients (n—21) were in Prince George visiting or for work-related purposes from cities 
including: Surrey, Edmonton, Bumaby, Kelowna, and Hixon.
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Figure 7. Classification of Patient Cases
Classification of patient cases by diagnosis is presented. The most common category of 
ACS was NSTEMI representing 42.6% of the total ACS cases (n=l 13). Unstable angina 
cases came in second with 32.8% of patients (n=87) and STEMI cases comprised the 
remaining 24.8% of patient cases (n=65).
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Figure 8. Classification of Patients given thrombolytics by diagnosis
A total of 15.5% of patients (n=41) across all diagnostic categories were administered 
thrombolytic therapy. Of these 15.5%, 14.6% of patients (n=6) were diagnosed as UA, 
24.4 % of patients (n=10) were NSTEMI and 61% of patients (n=25) were STEMI.
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Figure 9. Patient Discharge Status from UHNBC
Roughly 50% (n=124) of patients presenting to UHNBC with ACS were transferred to 
St. Paul’s Hospital (SPH). Over a quarter of patients (n=70) were sent to Vancouver 
General Hospital (VGH). 14% of patients (n=37) were deemed unsuitable candidates for 
PCI and were either sent home or to an extended care facility. There were 3.4% (n=9) of 
patients presenting to UHNBC with ACS that died from the condition, of which 22.2% 
(n=2) died while waiting for transfer to the cardiac catherization lab.
63
« 6 
3
>> 5
5w
*S 4
J3
Eo3fi JJU
« 2CO«
1 '
6.19
3.52
UA
n=87
NSTEMI
n=113
STEMI
n=65
Diagnosis
Figure 10. Average length of hospital stay according to diagnosis
The length of hospital stay among all patients with ACS regardless of transfer to a 
catherization lab was found to be the highest among patients with NSTEMI at an average 
of 6.19 days. Unstable angina came in second with an average of 5.2 days while STEMI 
patients remained in hospital for an average of 3.52 days. The two STEMI patients that 
died from cardiac events while awaiting transfer waited 14-48 hours before death.
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Figure 11. Average length of hospital stay prior to transfer according to diagnosis
The average length of stay prior to transfer to the catherization lab was 4.91 days. It 
found to be the highest among patients with unstable angina at an average o f 5.57 days. 
NSTEMI came in second with an average of 5.24 days while STEMI patients waited an 
average of 3.54 days prior to transfer.
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Figure 12. GRACE risk score by diagnosis
The GRACE risk score for both admission to in-hospital and admission to six months 
was the lowest among patients with unstable angina at an average score of 103.02 and 
102.59 respectively. NSTEMI cases had an average GRACE risk score of admission to 
in-hospital score of 133.61 and an admission to six months score of 124.26. STEMI cases 
had the highest GRACE risk score of 155.41 and 136.29 for in admission to in-hospital 
and admission to six months respectively. The largest decrease in risk status from 
admission to in-hospital to admission to six months was seen among patients with 
STEMI and the smallest decrease was among those with UA.
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Adverse outcomes for patients were determined at 30 days and one year of 
admission. The primary clinical endpoint was a combined measure of death, re-infarction, 
heart-failure, or stroke. It was found that a total of 6.04% of patients (n=16) suffered from 
adverse outcomes within 30-days of hospital admission for ACS. Of these patients 37.5% 
(n=6) belonged to the UA group, 25% (n=4) to the NSTEMI group and the remaining 
37.5% of patients (n=6) were STEMI patients. At the one-year mark, 12.1% of patients 
were found to have suffered adverse outcomes. Of these patients 50% (n=16) were from 
the UA group, and 25% each (n=8) were NSTEMI and (n=8) were STEMI patients. Due 
to the number of patients suffering from adverse outcomes being less than 50 as required 
for the statistical significance for the software, IBM SPSS v. 21.0, multiple logistical 
linear regression analyses for this objective was not possible, however a scatterplot was 
created to display this data (Figure 13.).
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Figure 13. Adverse outcomes for 30-day (circles) and 1-year (line) post-ACS 
admission as per length of hospital stay (x-axis)
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Table 6. Multiple linear logistical regression analysis of predictors for time to PCI
Model
Non-standardized
Coeffiecients
Standardized
Coefficients
t Sig.
B Std. Error Beta
Constant -4.947 6.261 -.790 .432
GRACE .044 .045 .546 .977 .331
InHosp
GRACE6mos
-.047 .065 -.438 -.724 .471
Age
.157 .077 .347 2.056 .043
Sex
-1.531 1.089 -.152 -1.405 .164
BMI
.093 .106 .095 .876 .384
Htn
1.560 1.117 .160 1.396 .166
Diabetes
-1.031 1.330 -.091 -.775 .440
a. Dependent Variable: PCI
b. Predictors: (Constant), Diabetes, Gender, BMI, Age, Hypertension, 
GRACEInHosp, GRACE6mos
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Multiple logistical linear regression analysis was used to test if  the patients were 
transferred for and received PCI according to their GRACE risk score of combined 
probability of death or reinfarction both from admission to course in hospital and from 
admission to 6 months. The results of the multiple linear regression indicated that patient 
age was the only significant predictor of time to PCI. Age explained 5.7 % of the 
variance in the outcome of time to PCI (R2=0.131, F(1.772), p <0.43). The other 
predictors including: diabetes mellitus, gender, BMI, hypertension and GRACE risk 
score (both admission to in-hospital and admission to six months) were found to be 
insignificant predictors of when patients received their PCI treatment.
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CHAPTER FIVE: DISCUSSION & CONCLUSION
The primary objective of the present study was to examine the issue of access to 
percutaneous coronary intervention (PCI) among patients presenting to the emergency 
department at the University Hospital in Northern British Columbia in Prince George. 
Specifically, this study aimed to determine whether the time delay to PCI was associated 
with more adverse outcomes, namely stroke, death or re-infarction at 30 days and 
whether the sickest patients, as risk stratified using the GRACE risk score, received care 
in the least amount of time.
The following chapter will interpret the results of the aforementioned research 
objectives and will discuss strengths and limitations of the study. Implications for future 
research, policy and practice will be presented in some detail. Finally, recommendations 
arising from the findings of this study will be made alongside concluding remarks.
Hypothesis 1: Longer times to treatment for PCI are associated with higher rates of 
adverse outcomes including stroke, death and re-infarction.
The first objective of this study was to explore associations among longer times to 
PCI treatment and adverse patient health outcomes, including a) stroke, b) death and/or c) 
re-infarction. Due to statistical software limitations, the sample size for adverse outcomes 
was insufficient, as was required for SPSS to run multiple linear regression analysis, 
therefore it was not possible to determine this association quantitatively. However, times 
to PCI and occurrences of stroke, death or re-infarction were calculated.
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The average time to PCI across all diagnostic categories was determined to be 5.9 
days. The average time to PCI for each type of ACS was 6.5, 6.2 and 3.8 days for UA, 
NSTEMI and STEMI respectively. The shortest length of stay prior to transfer was 
among the highest-acuity patients with STEMI, however the GRACE scores did not 
necessarily reflect this as the only significant predictor of patient transfer was age. A 
plausible explanation to this could be that length of stay was presented as an average thus 
may not accurately reflect the range of days STEMI patients waited for transfer. 
Furthermore, transfer may be strictly based on symptoms, diagnostic findings and clinical 
evaluation which depending on time of patient presentation may not accurately reflect 
patient risk status.
Furthermore, these results reveal an important discrepancy between the current 
best-practice guidelines and patients in a real-world setting. As previously mentioned in 
the first chapter, ACC/AHA guidelines recommend PPCI with 90 minutes and rescue or 
facilitated PCI within 120 minutes. The average times for PCI patients are clearly not 
meeting these guidelines primarily due to large distance required for transport of patients 
for care. Furthermore, the Canadian Cardiovascular Society (CCS) position statement on 
benchmarks as outlined in the first chapter for access to treatment state that diagnostic 
catherization and PCI for inpatients should be conducted within five days (Canadian 
Cardiovascular Society, 2011). Upon examination of the current times to treatment, it is 
evident that there is clear need for further improvements to reducing this delay in the 
population studied. Additionally, it is worth noting that two STEMI patients died from 
cardiac events while awaiting transfer to the cardiac catherization lab.
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While there were no documented reasons for this delay in patient charts, there are 
several plausible explanations for this delay as it may result in part in relation to the long­
distance transport required for access to the procedure (Sorenson et al., 2010). First, there 
are many organizational factors including delayed triage, and evaluation and diagnosis, 
which can delay a patient’s transfer such as understaffed emergency departments. In 
addition, patients presenting to rural hospitals may be cared for by physicians other than 
cardiologists, thus may not receive the latest evidence-based care (Pesut et al., 2013). To 
the same effect, patients may present with symptoms not typical of ACS that would 
require further diagnostics tests to reach a concrete diagnosis which can delay treatment. 
Second, the receiving hospital with catherization lab capability may also have 
organizational factors contributing to delay. These include: lack of available beds, their 
own patient populations within catchment areas, patient transfers from other community 
hospitals and operational restrictions of a Monday to Friday eight hour time-frame. Third, 
for patients requiring PCI in the winter months, the harsh northern winter climate can 
make for unsafe travelling conditions. In such circumstances, there is little that can be 
done to make conditions more favorable. Fourth, a patient may have one or more 
comorbid conditions, which can make them less than desirable for immediate transfer 
thus increasing times to treatment. Fifth, BC Air Ambulance is operational on a 8am-8pm 
basis which restricts the time frame of patient transfer (BC Ambulance Service, 2013). 
Furthermore, this may be complicated by a number of other factors external to the health 
care environment. For example, there may be presentation delay by patients post­
symptom onset while other patients may be adamant that they wish to receive care at a
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specific centre based on their prior experience either personally or otherwise (Henry et 
al., 2014).
A recent study by Nallamothu et al. (2006) found that patients with 
comorbidities, absence of chest pain, delayed presentation after initial symptom onset, 
less specific ECG findings or presentation to hospital during off-hours were found to 
have longer times to treatment. Additional studies have found that patients presenting to 
rural teaching hospitals also waited longer than those in urban teaching and non-teaching 
hospitals as well as rural non-teaching hospitals (Aguirre et al., 2008; Sorensen et al.,
2011). The increased wait times may be due in part to the effects of working 
environments seen in rural, often understaffed and resource limited, hospitals that can 
affect workload and can be further exacerbated due to the additional demands of 
instruction.
Some studies have examined ways to reduce this delay. While the focus of these 
strategies has been examined at facilities with PCI capabilities a small number of 
recommendations can also apply to transfer hospitals. Rezaee et al. (2010) found that 
initiating pre-hospital care including pre-hospital ECGs and pre-cardiac catherization lab 
activation by EMS led to an average of a 24-minute reduction. A study by Bradley et al. 
(2006) examined effective strategies to reduce delays in time to treatment for PCI. These 
strategies included having emergency medicine physicians activate the catheterization 
laboratory, having a single call to a central page operator activate the laboratory, having 
the emergency department activate the catheterization laboratory while the patient is en 
route to the hospital, expecting staff to arrive in the catheterization laboratory within 20 
minutes after being paged, having an attending cardiologist always on site, and having
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staff in the emergency department and the catheterization laboratory use real-time data 
feedback.
Adverse outcomes, namely a combined clinical endpoint resulting in death, re­
infarction, heart failure or stroke, were 7.3% and 14.6% at 30-days and 1-year post­
discharge respectively. Some studies have found that increased times to treatment have 
little effect on mortality (Brodie et al., 2001) while others have found that increased time 
to treatment not only increases mortality but infarct size as well (Angeja, 2002; Cannon 
et al., 2000). Therefore the results mortality due to delayed PCI remain inconclusive 
however best practice guidelines still stress that PCI should be carried out in a timely 
fashion. Timely care has been shown to improve overall patient outcomes including 
morbidity, stroke risk and re-infarction (Antman et al., 2008; Van de et al., 2008;
Boersma et al., 2006; Ross et al., 2006; Keeley et al., 2003; Nallamothu et al., 2003).
This is of relevance to the current study as results reveal UHNBC is not meeting 
provincial benchmarks therefore there is an urgent need to reduce this delay to treatment 
to avoid potential negative impacts on patient health.
Hypothesis 2: Patients are not transferred according to their risk status.
The second objective of this research was to explore the association between 
order of patient transfer and patient risk status. Patient time to PCI was not found to be 
associated with patient risk status. The only significant predictor of time to treatment is 
patient age. This finding was consistent with the literature as there has been repeated calls 
for there to be a formalized system to directly triage patients to cardiac catherization 
centres in order to reduce this time to treatment (Patel et al., 2010; Grines et al., 2002).
75
Current practice in Canada remains that patients requiring PCI are transferred on a ‘next 
suitable’ spot basis (Patel et al., 2010). Moreover, a risk-averse strategy seems to be in 
place when patient priority for transfer is assigned.
There are several plausible explanations for this current practice. First, the patient 
is required to be clinically stabilized before he or she is deemed safe for transfer via air 
ambulance. This stabilization may or may not correspond with the risk status of a patient. 
Additionally while this high-risk unstable patient is being stabilized, an opening at the 
receiving center may become available thus an already stable, yet lower-risk patient may 
be transferred first. Second, the current transfer of patients is based largely on ECG 
findings and clinical evaluation. Third, there tends to be a clinician bias as documented in 
the literature concerning the hesitation of clinicians to transfer overweight or obese 
patients due to risk of bleeding or other post-operative complications. This however is not 
always a correct assumption as several studies on the ‘obesity paradox’ have 
demonstrated that overweight or obese patients tend to have a lower incidence of post­
operative complications when compared to their lean counterparts (Hastie et al., 2010; 
Lancefield et al., 2010; Diercks et al., 2006; Gruberg et al., 2002). Furthermore high BMI 
has been found to be an insignificant predictor of short and long-term mortality, 
demonstrated by an inverse relationship between high BMI and patient mortality 
(Schenkeveld et al., 2012).
Regardless of these considerations the GRACE risk score provides a valid 
alternative to aid in the risk stratification of patients. It is a readily available tool on 
mobile devices and can become part of a clinician’s bedside tool kit to inform the triage 
and transfer processes (Stracke et al., 2010; Fox et al., 2006). Furthermore it is important
76
to note that while there is a perception that current practice involves the use of the TIMI 
risk score at UHNBC to risk stratify patients with ACS, there was little evidence o f its 
use in patient charts reviewed for this study and use of it was sporadic at best. A potential 
barrier to this could be that the score requires there to be documentation of patient aspirin 
use for risk calculation (Yan et al., 2004). This information may or may not be 
documented in patient medication history and sometimes may be patient reported. In 
contrast, the GRACE risk score uses pre-collected basic clinical information which can 
be located in patient charts and does not require any information of patient drug use yet 
provides an equally if not superior risk prediction model (Fox et al., 2006; Ramsay et al., 
2007) with a higher degree of discrimination and predictive accuracy (Correira et al., 
2010; Elabarouni et al., 2009; Fox et al., 2006).
Secondary findings
The examination of demographics and cardiovascular history of the study 
population led to some important findings. First, the majority of patients presenting to 
UHNBC with ACS were from Prince George, however there were also patients from 
smaller community hospitals transferred to UHNBC for care. This finding speaks to the 
importance of having a regional hospital that is able to provide this level of care not 
available in the surrounding and more rural community hospitals.
The literature also highlights the importance of thrombolytic therapy in the 
absence of PPCI availability for patients with STEMI (Mckay et al., 2009; Nallamothu et 
al., 2003; Zijlstra et al., 2003). In this study, less than quarter of all patients received 
thrombolytic therapy, while 38.4% were patients with STEMI. A possible explanation to
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this may be that since thrombolytic therapy is not recommended in high-risk patients, this 
patient population represents a high-risk group. However, the fact that not all STEMI 
patients (excluding high-risk, contra-indicated patients) received thrombolysis requires 
further investigation. Furthermore, thrombolytic therapy was administered to patients 
with all types of ACS, albeit less frequently then STEMI. This practice, for which there 
were no documented reasons in patient charts, is in contradiction to the ACC/AHA 
guidelines which state that there is no benefit from thrombolysis for patients with 
NSTEMI or UA (Levine et al., 2011).
STEMI patients on average were two to three years younger than those with 
NSTEMI or UA. Furthermore, males were over-represented in each ACS category 
comprising over half of the patient population. Major risk factors were present in more 
than half of the patients and included age, hypertension, dyslipidemia. Other significant 
risk factors included obesity and prior cardiovascular history.
As mentioned in the first chapter, a report by Cardiac Services BC (2011) 
highlights the presence of traditional risk factors in the northern population. This is also 
echoed in recent statistics published by Statistics Canada (2012). Traditional risk factors 
including obesity, diabetes, hypertension, smoking, physical inactivity and dyslipidemia 
are highly prevalent in northern residing populations. Furthermore, provincial prevalence 
of cardiovascular disease has remained stable over the last decade, but the NHA is the 
only health authority to see an increase during this time along with the higher than 
average provincial mortality rates (Cardiac Services BC, 2011).
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Study strengths and limitations
Research involving patient sensitive data and outcome analysis based on the 
current practices can be a challenging undertaking. The success of this research can 
depend on the acceptance and participation of organizations and professional groups who 
may be at varying levels of readiness to explore this area of investigation. Therefore this 
study strived to be collaborative in nature and sought input from academics, clinicians, 
organizations and other relevant stakeholders.
In addition to this, this study examined patients for a one-year duration. This 
allowed for a complete analysis of access to PCI for northern patients and accounted for 
any variability in access times influenced any uncontrollable factors. Factors such as 
adverse weather conditions affecting transport to the hospitals with catherization centres, 
or a larger-scale emergency such as a workplace accident or other disaster which can use 
resources and may take precedence over the immediate transfer of ACS patients.
Thirdly this study was the first of its kind to explore this issue for northern 
patients. It focused on exploring access for rural-dwelling patients, addressing a very 
important knowledge gap in the research domain as the majority of literature centered 
around large urban settings. It focused on the issue of access in both a unique 
geographical setting as well as on a distinct rural population.
There are certain limitations to keep in mind when considering this study. First, 
this study was limited to patients presenting to UHNBC and therefore may not be fully 
representative of the smaller, more remote community hospitals in northern BC. Second, 
the study population was limited to patients presenting directly to the emergency
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department at UHNBC. This excluded patients who experienced ACS as inpatients as 
well as patients transferred from smaller community hospitals who had already had their 
cardiac catherization lab referral process initiated prior to transfer to UHNBC. Third, data 
was collected from medical records, which typically do not contain data collected for 
research purposes so there is a possibility of some variation or inaccuracies in the dataset.
Key findings and contributions
To our knowledge, this study is the first of its kind to be conducted in northern 
BC on this topic. It uses an exploratory approach to respond to an important and pressing 
health care issue. It offers insights that cannot be provided through the experience of 
large-scale randomized control trials that are centered in larger urban centres as the 
generalizability of these studies is limited in rural settings. It aimed to address this 
knowledge gap and to identify this population, their risk status and their access to PCI 
services.
Keeping in line with this, a strong effort will be made to disseminate the findings 
from this study using a knowledge translation (KT) strategy. The KT plan includes: a 
briefing summary to Northern Health, a webinar, conference presentations and 
manuscript publications. This will ensure that the results are made available to key 
decision makers, stakeholders and health care practitioners.
Recommendations
There are certain recommendations that can be made from the results of this 
study. This study was focused on ACS patients presenting to one centre within the 
Northern Health Authority region. Therefore, a larger scale study covering the entire
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Northern Health Authority region can be warranted. This would provide a complete 
picture of access to cardiac services in all of the north. It would enable a look into access 
to PCI for all northern patients and provide information concerning risk status, length of 
patient hospital stay among other factors. It would be beneficial to compare these trends 
among different areas of the north to see differences and similarities within the northern 
context. Furthermore, a larger scale study would allow for meaningful logistical 
regression analysis to study the relationship between adverse outcomes and length of stay 
prior to transfer for PCI.
Second, a look into all factors which can influence wait times for PCI is valid. 
Factors such as the process for transferring patients via BC Air Ambulance, the 
respective catherization labs procedures and their respective processes, and the referral 
process for each of the catherization labs. This would allow for the determination of 
possible areas of improvement as well as the identification of a standardized process of 
‘best practices’ for transfer patients. Alongside this a look into the feasibility of a 
dedicated network for patient transfer to reduce transport related delay is also warranted.
Third, an exploration of developing a formal triage process for all ACS patients 
should be explored. This process should be standardized across all provincial cardiac 
catherization labs to ensure equitable access to treatment. Furthermore, in hospitals 
without cardiac catherization labs the development of a provincial patient priority system 
could potentially ensure that the sickest and highest risk patients would receive their care 
the fastest.
Fourth, it is worthwhile to examine the aspect of having a regional catherization
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lab in Prince George. There are two reasons to this. Patients receiving PCI typically 
receive same day discharge from the hospital after their procedure. Therefore having a 
regional catherization lab for the north could potentially reduce length of stay for patients 
resulting in a cost savings for the health authority related to the number of ‘bed days’ 
used for patients awaiting transfer as well as the cost of an air-ambulance transfer.
According to the Canadian Centre for Policy Alternatives (2012) the average cost 
of treating a patient in hospital ranges from $825-$ 1968 per day and can vary depending 
on the patient’s individual circumstances including diagnosis, level of acuity and 
comorbid conditions. The cost o f an air ambulance for transfer of patients at UHNBC is 
as follows. Due to UHNBC not having a rooftop helipad, patients are transferred to the 
Prince George International Airport, using a ground air ambulance at cost of $530 per 
patient (BC Ambulance Service, 2013). From the airport, air ambulance transfer of 
patients is costed at $2746 per hour of travel. Furthermore, obese patients may require the 
use of a bariatric plane which costs $7 per statue mile (BC Ambulance Service, 2013). 
Additionally a cardiac catherization lab would be able to perform procedures other than 
PCI, such as CABG which can result better long-term patient outcomes for certain 
patients such as those with complex lesions (Mohr et al., 2013). This would not only 
improve patient outcomes but would enable the triage of patients for medical treatment 
versus cardiac intervention (PCI or CABG) saving angiography times in the larger 
centres and resulting in lower costs to the overall health care system.
Given the results of this study, a large majority of the patients are high risk with 
multiple co-morbidities or are elderly which can result in an even larger expenditure 
related to cost of hospital stay. As well the bed utilization for patients awaiting transfer
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may also impact services for other patients. According to the BC Medical Association 
(2008), this can result in the cancellation of scheduled procedures for other patients. 
Furthermore, UHNBC does not have a critical care unit (CCU) and high-risk cardiac 
patients such as those requiring telemetry beds are placed in the intensive care unit (ICU) 
which can potentially limit the number of beds and consequently level of care required 
for non-cardiac but acutely ill patients requiring ICU care. As well, there are also out-of 
pocket costs for patients associated with travelling for care. For example, the Medical 
Services Plan (MSP) does not cover travel costs associated with patient travel from the 
cardiac catherization centre back to Prince George unless the patient is medically unfit 
and requires repatriation to UHNBC (BC Ambulance Service, 2013).
Furthermore, having a catherization lab in Prince George could reduce costs 
associated with other northern patients. It would potentially save the smaller community 
hospitals from having to keep their patients in hospital prior to transfer. It may also 
reduce the burden o f cost associated with patient transfer through BC Ambulance due to 
shorter travel distances from northern communities to Prince George as compared to the 
Lower Mainland. This is consistent with research done by Le May et al. (2003) who 
discovered that in Canadian centers in which facilities and experienced interventionists 
are available, primary stenting (n=62) was less costly and more effective than 
thrombolysis (n=61).
However this requires the consideration of a number of complex financial and 
health care service factors given the current context. A detailed analysis of the literature 
alongside an examination of the practicality and feasibility o f such a facility is warranted 
as there is considerable debate concerning the creation of stand-alone PCI centres.
83
Concerns include the sustainability of the system in terms of staffing levels as they 
require continuous and/or on-call staffing, infrastructure and patient volumes. This is 
particularly relevant in rural communities where the recruitment and retention of health 
care professionals can be challenging at best.
Finally, an examination into patient experiences associated with treatment delay 
may also provide valuable insight into this issue. This would include an examination of 
factors associated with patient delays to seeking treatment as well as an exploration of the 
patient journey in the process including emotional, physical, psychological and financial 
constraints. The findings from this work could help to inform future initiatives and 
planning to improve current practices and procedures.
Implications for research
The findings from this study present several areas for future investigation. To 
build on the findings from this exploratory study, a longitudinal study encompassing all 
hospitals within the boundaries of the Northern Health Authority could examine transfer 
times, and patient health outcomes. In addition to this, a study exploring the 
organizational barriers both at the transfer and receiving hospitals is needed. Equally as 
important would be an exploration of the logistics of current patient transfer via air 
ambulance through the BC Ambulance Service.
Implications for policy and practice
For hospitals without on-site cardiac catherization facilities, using transfer 
strategies there is a need to be cognizant of their own times to transfer. Attention to this 
can aid in process improvements which in turn can reduce the overall delay from time of
84
presentation to balloon time. This information can also be incorporated into clinical 
decision making when selecting between reperfusion strategies.
As a starting point, more attention to documentation of cardiac patients would be 
ideal. For example, having the documentation of cardiac referral times for all patients 
would allow for the identification of referral to transfer time. This in turn would allow for 
indication as to the delay in time at the transfer hospital. Furthermore, it would allow for 
the opportunity to identify the time of delay from point of referral to transfer.
Second, this study presents an alternative to the current practice of TIMI risk 
score use at UHNBC. The GRACE risk score is a validated risk prediction tool for 
implementation in prioritizing patient transfer for cardiac intervention. The use of this 
tool may also assist physicians, who are less likely to be specialist internists, in smaller, 
more rural community hospitals with triaging and prioritizing patients for transfer.. Thus 
the implementation of this risk stratification tool can have immediate effects on assisting 
physicians in their clinical decision making.
Third, there may be scope to introduce pre-hospital thrombolytic therapy, and pre­
hospital ECGs for eligible patients by ambulance paramedics, a method endorsed by the 
ACC/AHA (Levine et al., 2011). This is general practice in some parts of the world 
including Europe and is strongly encouraged by the European Society of Cardiology 
(ESC), despite the existence of a larger number of PCI-capable hospitals and shorter 
distances to them (Van der Werf et al., 2008). While it’s implementation in North 
America is somewhat limited, certain Canadian cities including Houston (NS) and 
Edmonton (Alta) have managed to demonstrate some level of success in terms of
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improved patient outcomes with its use (Huynh et al., 2011). This would allow for a 
potential reduction in infarct size, limiting myocardial damage. Furthermore, the more 
acute patients may then be eligible for faster transfer for PCI (Rezaee et al., 2010).
The findings from this research also present some important opportunities for 
public health strategies. These include targeted obesity reduction approaches, smoking 
cessation campaigns, and healthier lifestyle interventions for high-risk patients. These 
public health interventions could be tailored to the high-risk patients and potentially 
reduce repeat visits and consequently repeat admissions to UHNBC.
Conclusion
In summary age was the only significant predictor of time to treatment for PCI. 
Furthermore, it was evident that a risk-averse strategy was adopted and transfer of 
patients was largely based on factors including clinical presentation rather than risk 
status. While PCI remains the treatment of choice for patients with ACS, particularly 
STEMI, thrombolytic therapy still offers a reasonable alternative in hospitals without on­
site cardiac catherization facilities. Furthermore, under certain conditions, transfer for 
PCI despite prolonged time to treatment may still be the best option as the research 
surrounding patient transfer for PPCI remains somewhat inconclusive. It is hoped that the 
results from this study will provide a baseline for further research and allow decision 
makers to understand the current transfer situation and risk profiles of northern patient 
populations.
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APPENDICES
Appendix A: Corresponding ICD-9 Codes
Disease Term ICD Number
Angina Pectoris 120
Unstable Angina 120.0
Acute Transmural myocardial infarction of anterior wall 121.0
Acute Transmural myocardial infarction of other sites 121.2
Acute Transmural myocardial infarction of unspecified site 121.3
Acute subendothelial myocardial infarction 121.9
Subsequent myocardial infarction of anterior wall 122.0
Subsequent myocardial infarction of inferior wall 122.1
Subsequent myocardial infarction of other sites 122.8
Subsequent myocardial infarction of unspecified site 122.9
Post myocardial infarction angina as current complication following acute 
myocardial infarction
123.2
Other acute ischaemic heart disease 124
Coronary thrombosis not resulting in acute myocardial infarction 124.0
Other forms of acute ischaemic heart disease 124.8
Acute ischaemic heart disease, unspecified 124.9
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Appendix B: STEMI Protocol
j / r
n o rth e rn  health
Prince George Regional Hospital
PHYSICIAN S ORDERS
ST ELEVATION
MYOCARDIAL INFARCTION
Date:
□□□
□
Patient Weight: _ Door Time: First ECG:
1 .
2.
3.
4.
5.
6 . 
7.
Admit to CCU and implement Physician's Orders for Coronary Routine. 
Morphine 2 - 5 mg IV pm for chest pain.
Chew 2 x 80 mg ASA slat (check allergies first).
Initiate 2 IVs (#18 - 20) in opposite arms.
CBC, SeCr, PT, PTT @  baseline, then CBC q3days 
Enteric Coated ASA 325 mg po daily.
Choose one of the following .
I____ L
Enoxaparin 30 mg IV bolus before TNK.
TNK weight adjusted bolus over 5 sac.
Enoxaparin 1 mcVka ftnax 100 rrw) SC now. then BID x 7 days.
fi ;m He;> 
'j v . ’' .  • e  > •'! O  C< • .0 >' I on!' rju
TNK weight adjusted botus over S sec.
Hepartn nomogram on reverse with first aPTT 3 hours post TNK.
| H  Patient Weight w TNK (me) Volume (mt)
I B  <60 30 6
|K §  60-<70 35 7
wm 70 - < 80 40 8
80-<90 45 8
■  >90 50 10
To use the Table: ^
Select age and gender to 
identify SeCr cut-off value. 
Values above cut-off 
indicate a CrCI < 30 mL/min 
& enoxaparin should not be 
used.
□ 9.□ 10.□ 11.
12
13.a 14
15.
16.
17
II admission blood glucose > 11.0, initiate DIGAMt protocol.
Beta Blocker: Choose one of the following:
□  IV Metoprolol 5 mg over 2 minutes & repeat q5min x 3 doses 
(total * 15 mg) (consider dosage reduction if patient already on beta 
blocker or calcium channel blocker).
□  Oral Metoprolol _________        starting at _
Clopidogrel 300 mg po stat and 75 mg po daily.
Lipitor 80 mg po daily or mg po daily (No Substitutions)
ACE Inhibitor:
1 2 -
Male Age Female
300 40 255
285 45 242
270 50 230
255 55 216
240 60 204
225 65 191
210 70 178
195 75 165
180 80 153
165 85 140
150 90 127
hours
starting a t.......................hours
■ lead ECG 90 minutes post TNK 
Cholesterol, triglycerides, HDL , LDL. fasting glucose within 24 hours of admission. 
Smoking Cessation Initiate Nicotine Withdrawal Protocol.
Cardiac Rehab Coordinator referral (fax: 250-565-2084)
Pharmacist to review medications on day 4.
Dietitican Consult (fax. 250-565-2889).
Physician's Signature:
IFD Form *11-100-1049 REVUO'pc
Time: Date:
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Appendix C: NSTEMI/UA Protocol
...
^  northern health
Prince G eorge R egional H ospital
ACUTE CORONARY SYNDROME 
O R D E R S FO R UA/NSTEMI
C o n s i d e r  t h e  f o l lo w in g  a s  p e r  R is k  S t r a t i f i c a t i o n  ( o n  r e v e r s e )  indicate with a check  ( / )  fo r y e s
1. I n i t ia te  P h y s i c i a n ’s  O r d e r s  f o r  C o r o n a r y  R o u t in e  -----------------------
_  P a t i e n t  W e ig h t2. O  Telem etry QR *
O lC U
(<J  3. ASA (ch o o se  one)
( 3  ECASA 81 mg po daily
  ( 3  ECASA 325 mg po daily
□  4. N itroglycerin
( 3  Patch strength____________ apply qam and remove qhs
O  Infusion beginning at 5 mcg/mln & titrate to pain and BP a s  per protocol (ICU / ER only)
Q  5. B eta Blocker
( 3  Metoproiol
O  IV 5 mg bolus x  doses at intervals of_______ minutes (max 15 mg)
O Oral___________mg po every______ hours starting at__________ _ hours
C 3 Other Beta b lo c k e r______________________mg po every_______hours starting at___________hours
Calcium  C hannel B locker _______________ „_____ mg po - frequency_______________
Clopidogrel 300 mg po stat and 75 mg po daify.
Lipitor 80 mg po daily o r __________ mg po daily. (No Substitutions)
R am ipril_____________ mg po qam
10. A nticoagulan ts
< 3  Enoxaparin 1 mg/kg q12h and CBC Mondays & Thursdays (if CrCI < 30 mL/min. use UFH)
( 3  Heparin (as per protocol)
Eptifibatide (In tern ists only)
( 3  For patients with CrCI > 30 mL/min
•  Loading d ose  180 mcg/kg = _____ meg (max 22.6 mg) over 2 minutes
•  M aintenance dose  2 mcg/kg/min ■   mcg/min (max 15 mg/hour) x _______ hours (max 72 hrs)
( 3  F° r patients with CrCI < 30 mL/min
•  Loading dose 180 mcg/kg = _________meg (max 22.6 mg) over 2 minutes
•  M aintenance dose 1 mcg/kg/min * _______ mcg/min (max 7.5 mg/hour) x  ..... h o u rs  (max 72 hrs)
•  CBC 4 hours post initiation of Eptifibatide and daily thereafter x 4 days
□  12. If chest pain unresponsive to Nitroglycerin spray given three times 3 - 5 minutes apart, give Morphine
S u lphate   mg (V  q _______ minutes pm, request STAT ECG and notify physician.
13. Cholesterol. Triglycerides, HDL, LDL. fasting sugar within 24 hours of admission.
□  14. Smoking Cessation NICC referral (fax: 250-612-0810) consider Nicotine Replacement.
15. Cardiac Rehab Coordinator referral (fax: 250-562-2084)
16. Pharmacist to review medications on day 4
17. Dietician consult (fax: 250-565-2889)
Physician's S ignature:__        D ate.............. ..........  _.. . .................. ..
C D R  F orm  « 1 1 -100 -1023  DRAFT # 6  - 0 4 /0 7 p c
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Appendix D: Cardiac Catherization Lab Referral Form
Cardiac Cath Lab Referral
.. ................\ _ /  Mm f  ts9«ptm
Va ^ u v m h o s m t a L
i  IflMI l l i t l tH  (MU*
Nam*:
Address:
DOB:
PHN:
Tofephono: 
Roferrtl Data:
pp)f: referral form, history. ECG. lab m u t ts ,  echo raoort. ETT. CXR. m ads
m savnrm m
Fax: 604-875-5142 Fsx: 604-806-6637 
Phone: 604-875-4669 Phona: 604-806-8051
Rsfarrina MD:
Reforrlna tel:
Reforrlna fax:
First Available Cardiologist a  
Soactflc Cardioloaiat:
Angiogram /  PCI within tha last yaar by 
Or.
Urgency
O InpaSert Hospital:
3  Emergent (pone without delay)
3  Ut (before hospital dechsrgs) Q suitable lor same day Oschg 
Q Outpatient Q Elective
3  Semkumsnt: reason
- VH: M447S4111 SPH: 104412-2344
Procedure^)
Requested:
Q DiegnosSc Catheterteation
a  Cath & Possible pci 
a  PCI (cath dona)
□  Right Heart Cath
a  Pulmonary Resistance
□ Ranal angiogram
□  Aortogrem
O CarotkMvesael study
□  Biopsy
□  Othar
Indication: Meats Drovide sinale heat Indication and ahre detest If this is an ACS
ACS Onset pate:Acute Coronary Syndromes
STEMI:_ ACS Pain or lachamta:#Fibrinolysis: data/time:_____
_  _ ___ _ □ Ongoing (no complete reset)O  Direct PCI (no (Ibrinolysa)
3  Recursnt (speodrc •vonts;
O  Rescue (fated thrombolysis)
3  Provokabia (on stress test)
O  Fncrktated (tnromobotysh ♦ PCI)
_  _ , _____ 3  None (scula event aettied)Q  Post acuta STEMI
NSTEMI or othar ACS:_  ACS Medications:
O troponin 1 marker*
____ ___a  GPHMIIaInhibitora  ischemic ECG change (ST or T)
3  Heparin IV or LMWH
3  equrvocai or no marker rise
3IVNTG
a  Stable CAO
CCS Angina Claes.
0 t II III IV 
Valve 3  aortic 3  mitral
□ CHF NYHA Class: 1 It HI 
IV
3  Dilated CM 
Q Hypertrophic CM 
Arrhythmic VTIVF3 SVTO 
3  Congenital
□ Post Transplant
Q Research Protocol only
Other riak factors 
3  hyperiipidemla 
□ currant smoker 
Height: _ _ _ _ _  
Weight:
Prior non-lnvaaiva tes ts : 
Not done 3  
a  Pas 
3  Neg 
3  Unk
3  indaterminata
Safety:
3  ASA admmielsred 
3  Plavix administered 
3  Contrast allergy 
3  Warfarin 3  mechanical valve 
□ Metformin
Renal status Last creatinine
Complexity:
3  None 3  Ola betas 
3  PVO 3  CHF (current) 
3  Prior Ml 3  Hypertension 
3  Prior PCI 3  Prior CABG 
3  Shock
3  Other disease hrttinq siavival
QAIMLA&.USE QUL1
Antlcoagulatton Rlik Low Intermadtate High 
atop Warfarin 4-5 days pn»-procedure 
Bndge
PO HOT stop Warfarin
2** Interventional opinion 3  
Surgical opinion Q 
p -  e Research Protocol 
i on Only 3
lii ti. l.m.,, Lmlk, .
Referring Physician History SComments: 
Referring Physician
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Appendix E: Hospital Transfer Form
W
§
t
' SV « *TM f E B B 8 U S B ^  m m m k x .
n Q U B M .m M tM m M ria K m im A  W M m a x .
a DO HOT
aivm aA Y Q em ocm tam  t a n  d a y  tm m m tm u m
m j | | « n v i a »  CM AAdfcndtt
O AM S t i n t  (3 AleMfeMpegfcfesinliB
O McMhiiiwli a AMIWBuiw^ n ^ ly.gMHdiMilurgHK^ fll. a .CNfMNj ralpM i t  a  AM IWBM» 1 >| 8UMMHI)
rrjrn '-*rj:ir.T.TiTTT
Ht_____CM m Mi BP,
Mmgum an o r  use___________
aw W d H M 3 « N lw M  »m  NFOlhrspw-pmaelwi.
CMNHnMlMln ON O r h i  H m
hjsb n w im n i f t r t l  l n r j * n .i  mwt n m t t l
im m m c o o  o n  a y
on a r
HblQikMMtarsc ON O Y
ttaparinMMm an O Y
LVrtVM O N  O Y  n m 111m ifcrtnttme
ASA ON O Y  LMtdoM________ m
O N  O Y  lam *m 4 a tm  am  d aM fe lW .
HOUk W M M i (M  d*y«) UM jdow________ rn*
M a d a m h i d q r s )  l A M d o w _ _ _ _ _ _ _ n V  d * W * n e .
&SSUZ&M »*** 24 hi* AN Aeeart pie *  port procedure
a  EnUr* c h it  (»ww w in  taM * M m*nd orJy) O Adn*MtavS«per*dan w ard
O CumntNMnry A pny tad  O I m w p w lw oim ry
□ Altabrmdi 0  Midi* alt dame
O S to rW w dfaaSonracwdfatdOT cdttsw ftr
(3 PtrinrvM  bMonOnge A a i omtwant rrwilarton tar nsod <l*y 
hofnefarri✓ a  Panned transportation tofre far rad  day dtedharse
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Appendix F: Grace Risk Score ACS Models
ACS Risk Model
At A dm ission (in-hospltal/to 6  m onths) ] f A t D isch a rg e  (to  6  m onths)
Age (Years
HR bpm
SBP mmHg
Creat. (nmoiyi
CHF KiHip Class
II
|  US Units \
3
■  Cardiac arresl at admission
■  ST-segment deviation
■  Elevated cardiac enzymes/markers
Probability of Death Death or Ml 
In-hospital 
To 6 months
Reset D
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Appendix G: PCI Studies Summarized
Study Patient
/Pop.
Intervention Control Outcome
Widimisk 
y et al. 
(2000)
PRAGUE
TRIAL
N=300 Thrombolysis 
during 
transfer for 
PCI (group B) 
OR
immediate 
transfer for 
PPCI (group 
C)
Thrombolysis 
at a
community 
hospital 
(group A)
Combined primary end-point (death 
or reinfarction and/or stroke at 30 
days) was less frequent in group C 
(8%) compared to both groups B 
(15%) and A (23%, p<0.02)
Incidence of reinfarction was 
markedly reduced by transport to 
PPCI (1% in group C vs 7% in group 
B vs 10% in group A, p<0.03)
The transfer of patients from a 
community hospital to a PCI centre in 
the acute phase of AMI is both safe 
and feasible and is associated with 
significant reduction in incidence of 
reinfarction and combined primary 
endpoint (death or reinfarction and/or 
stroke at 30 days)
Widimsky et 
al. (2003)
PRAGUE-2
TRIAL
N=850 Immediate 
transfer for 
PPCI (PCI 
group)
Thrombolysis 
at a
community 
hospital (TL 
group)
Mortality at 30 days was higher 
(10.0%) in the TL group compared to 
6 .8% mortality in the PCI group 
(p=0 .12, intention-to-treat analysis). 
Mortality of 380 patients who actually 
underwent PCI was 6.0% vs 10.4% 
mortality in 424 patients who finally 
received thrombolysis, TL group 
(p<0.05). Among the 299 patients 
randomized >3 hours after the onset 
of symptoms, the mortality of the TL 
group was higher (15.3% compared to 
the PCI group (6%, p<0.02). Patients 
randomized <3 hours of symptom 
onset (n=551) had no difference in
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mortality whether treated by TL 
(7.4%) or transferred for PCI (7.3%). 
A combined end-point occurred was 
higher in the TL group (15.2%) vs the 
PCI group (8.4%, p<0/003)of the PCI 
group
Long distance transport from a 
community hospital to a tertiary PCI 
centre in the acute phase of AMI is 
safe as this strategy was associated 
with marked decreases in mortality in 
patients presenting more than 3 hours 
after symptom onset. However for 
patients presenting within 3 hours of 
symptom onset, TL results were 
similar to the results in long distance 
transport for PCI
Ellis et al. 
(2004)
FINESSE
TRIAL
N=300
0
PPCI 2 facilitated
PCI
treatments; 
reduced-dose 
reteplase and 
abciximab 
combination 
therapy OR 
abciximab 
alone
followed by 
PCI with 
abciximab 
alone
One-year mortalities in the three 
groups, reduced-dose reteplase and 
abciximab combination therapy 
(6.3%) or abciximab alone followed 
by PCI with abciximab alone (7.4%), 
or PPCI, r (7.0, p = NS), representing 
1.1%, 1.9%, and 2.5% increments 
since the 90-day outcome (p = 0.053 
for combination treatment vs PPCI)
Widespread use of facilitated PCI 
could not be justified among all ACS 
patients but high-risk (i.e with anterior 
AMI) deserve further study
Femandez- 
Aviles et al. 
(2007)
GRACIA-2
N=212 PPCI with 
abciximab <3 
hours of
randomization
Full
tenecteplase 
followed by 
stenting 
within 3-12 
hours of 
randomization
Early routine post-thrombolysis PCI 
resulted in higher frequency (21 
versus 6%, p = 0.003) of complete 
epicardial and myocardial reperfusion 
(TIMI 3 epicardial flow and TIMI 3 
myocardial perfusion and resolution 
of the initial sum of ST-segment
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TRIAL (early routine 
post­
thrombolysis 
PCI
elevation > or = 70%) following 
angioplasty. Both groups were similar 
regarding infarct size (area under the 
curve of CK-MB: 4613 +/- 3373 vs 
4649 +/- 3632 microg/L/h, p= 0.94); 
6-week left ventricular function 
(ejection fraction: 59.0 +/-11.6 vs 
56.2 +/-13.2%, p= 0.11; end systolic 
volume index: 27.2 +/-12.8 vs 29.7 
+/-13.6, p = 0 .21); major bleeding 
(1.9 vs 2.8%, p = 0.99) and 6-month 
cumulative incidence of the clinical 
endpoint (10 vs 12%, p = 0.57; RR: 
0.80; 95% Cl: 0.37-1.74)
Early routine post-fibrinolysis 
angioplasty safely results in better 
myocardial perfusion than primary 
angioplasty as despite its delayed 
application, this approach was seen to 
be equivalent to primary angioplasty 
in limiting infarct size and preserving 
left ventricular function
Grines et al. 
(2002)
AIR-PAMI
TRIAL
N=138 Transfer for 
PPCI
On-site
thrombolysis
Patients randomized to transfer had a 
reduced hospital stay (6.1 +/- 4.3 vs 
7.5 +/- 4.3 days, p= 0.015) and less 
ischemia (12.7% vs 31.8%, p =
0.007). At 30 days, a 38% reduction 
in major adverse cardiac events was 
observed for the transfer group 
however, because of the inability to 
recruit the necessary sample size, this 
did not achieve statistical significance 
(8.4% vs 13.6%, p = 0.331)
High-risk patients with AMI at 
hospitals without a catheterization 
laboratory may have an improved 
outcome when transferred for primary 
PCI versus on-site thrombolysis. This 
suggests that the marked delay in the
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transfer process suggests a role for 
triaging patients directly to 
specialized heart-attack centers
Andersen et 
al. (2003)
DAN AMI-2 
TRIAL
N=157
2
PPCI Thrombolysis The primary study end point was a 
composite of death, clinical evidence 
of reinfarction, or disabling stroke at 
30 days. Among patients who 
underwent randomization at referral 
hospitals, the primary end point was 
reached in 8.5% of the patients in the 
PCI group, as compared with 14.2% 
of those in the thrombolysis group 
(p=0.002). The results were similar 
among patients who were enrolled at 
invasive-treatment centers: 6.7% of 
the patients in the PCI group reached 
the primary end point, as compared 
with 12.3% in the thrombolysis group 
(p=0.05). Among all patients, the 
better outcome after PCI was driven 
primarily by a reduction in the rate of 
reinfarction (1.6% in the PCI group vs 
6.3% in the thrombolysis group, 
p<0 .001); no significant differences 
were observed in the rate o f death (6.6 
% vs 7.8 %, p=0.35) or the rate of 
stroke (1.1 % vs 2.0 %, p=0.15)
A strategy for reperfusion involving 
the transfer of patients to an invasive- 
treatment center for PPCI is superior 
to on-site thrombolysis, provided that 
the transfer takes two hours or less
Van der 
Werf et al. 
(2006)
N=166
7
PPCI with 6 
hours of 
STEMI
PCI preceded 
by
administration 
of full-dose
Primary endpoint (death, CHF, or 
shock) in 19% (151 of 810) of 
patients assigned facilitated PCI 
versus 13 % (110 of 819) of those
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ASSENT-4
TRIAL
tenecteplase randomised to PPCI (relative risk 
1.39, 95% Cl 1.11 -1.74; p=0.0045). 
During hospital stay, significantly 
more strokes (1.8% [15 of 829] vs 0, 
p<0 .0001), but not major non-cerebral 
bleeding complications (6% [46 of 
829] vs 4% [37 of 838], p=0.3118), 
were reported in patients assigned 
facilitated rather than standard PCI. 
We also noted more ischaemic cardiac 
complications, such as reinfarction 
(6% [49 of 805] vs 4% [30 of 820], 
p=0.0279) or repeat target vessel 
revascularisation (7% [53 of 805] vs 
3% [28 of 818], p=0.0041) within 90 
days in this study group
A strategy of full-dose tenecteplase 
with antithrombotic co-therapy, as 
used in this study and preceding PCI 
by 1-3 h, was associated with more 
major adverse events than PCI alone 
in STEMI and cannot be 
recommended.
Nielsen et al. 
(2010)
Follow-up to 
the
DAN AMI-2 
TRIAL
N=157
2
PPCI Thrombolysis The composite endpoints primarily, 
death, clinical re-infarction, or 
disabling stroke, were reduced by PCI 
when compared with thrombolysis at 
3 years (19.6% vs 25.2%, p= 0.006). 
For patients transferred to PCI 
compared with those receiving on-site 
thrombolysis, the composite endpoint 
occurred in 20.1% vs 26.7% (p= 
0.007), death in 13.6 vs 16.4% (p= 
0.18), clinical re-infarction in 8.9% vs 
12.3% (p= 0.05), and disabling stroke 
in 3.2% vs 4.7% (p= 0.23)
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The benefit of transfer for primary 
PCI based on the composite endpoint 
was sustained after 3 years. Nielsen et 
al. (2010) concluded that for patients 
with characteristics such as those in 
DANAMI-2, primary PCI should be 
the preferred treatment strategy 
provided that inter-hospital transfer 
can be completed within 2 hours
Thiele et al. 
(2011)
LIPSIA-
STEMI
TRIAL
N=162 PPCI (group 
B)
Pre-hospital- 
initiated 
facilitated 
PCI (group A)
Despite better pre-interventional TIMI 
(Thrombolysis In Myocardial 
Infarction) flow in Group A (71% 
versus 35% TIMI flow grade 2 or 3; p 
< 0 .001), the infarct size tended to be 
worse in group A vs group B (17.9% 
of left ventricle IQR: 8.4% to 35.0%) 
vs 13.7% IQR: 7.5% to 24.0%); p = 
0.10). There was also a strong trend 
toward more early and late 
microvascular obstruction, (p = 0.06 
and 0.09) and no difference in ST- 
segment resolution (p = 0.26). The 
combined clinical endpoint showed a 
trend toward higher event rates in 
group A (19.8% vs 13.6%; p = 0.13, 
RR: 0.52, 95% Cl: 0.23-1.18)
STEMI patients presenting early after 
symptom onset with relatively long 
transfer times, a thrombolytic-based 
facilitated PCI approach with optimal 
antiplatelet co-medication does not 
offer a benefit over primary PCI with 
respect to infarct size and tissue 
perfusion
Bohmer et 
al. (2003)
N=197 Transfer <6 
hours after 
thrombolysis
Elective PCI 
two weeks 
after
Immediate stenting was associated 
with a significant reduction of the 
combined end point after six months
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SIAM-III
TRIAL
for PCI thrombolysis (ischemic events, death, reinfarction, 
target lesion revascularization 25.6% 
vs 50.6%, p = 0.001)
Immediate stenting after thrombolysis 
leads to a significant reduction of 
cardiac events compared with a more 
conservative approach including 
delayed stenting after two weeks
Femandez- 
Aviles et al. 
(2004)
GRACIA-1 
TRIAL
N=500 PPCI Angiography 
or PCI within 
24 hours of 
thrombolysis
By comparison with patients receiving 
conservative treatment, by 1 year, 
patients in the invasive group had 
lower frequency of primary endpoint 
(23 (9%) vs 51 (21%), relative risk 
0.44 (95% Cl 0.28-0.70), p=0.0008), 
and they tended to have reduced rate 
of death or reinfarction (7% vs 12%, 
0.59 (0.33-1.05), p=0.07). Index time 
in hospital was shorter in the invasive 
group, with no differences in major 
bleeding or vascular complications.
At 30 days both groups had a similar 
incidence of cardiac events. In- 
hospital incidence of revascularisation 
induced by spontaneous recurrence of 
ischaemia was higher in patients in 
the conservative group than in those 
in the invasive group
In patients with STEMI, early post­
thrombolysis catheterization and 
appropriate intervention is safe and 
might be preferable to a conservative 
strategy since it reduces the need for 
unplanned in-hospital 
revascularization, and improves 1 - 
year clinical outcomes
I l l
Di Mario et 
al. (2008)
CARESS-in- 
AMI TRIAL
N=600 Thrombolysis
and
immediate 
transfer for 
PCI
Thrombolysis 
and transfer 
for rescue PCI
The primary endpoint was a 
composite o f death, reinfarction, or 
refractory ischaemia at 30 days. Of 
the 299 patients assigned to 
immediate PCI, 289 (97.0%) 
underwent angiography, and 255 
(85.6%) received PCI. Rescue PCI 
was done in 91 patients (30.3%) in the 
standard care/rescue PCI group. The 
primary outcome occurred in 13 
patients (4.4%) in the PPCI group 
compared with 32 (10.7%) in the 
standard care/rescue PCI group 
(hazard ratio 0.40; 95% Cl: 0.21-0.76, 
p=0.004). Major bleeding was seen in 
ten patients in the immediate group 
and seven in the standard care/rescue 
group (3.4% vs 2.3%, p=0.47).
Strokes occurred in two patients in the 
immediate group and four in the 
standard care/rescue group (0.7% vs 
1.3%, p=0.50)
Immediate transfer for PCI improves 
outcome in high-risk patients with 
STEMI treated at a non-interventional 
centre with half-dose reteplase and 
abciximab
Bohmer et 
al. (2007)
NORDSTE
MI
TRIAL
N=266 Immediate 
transfer for 
angiography 
OR PPCI
Thrombolysis 
in the
community 
hospitals, 
with urgent 
transfer only 
for a rescue 
indication or 
with clinical 
deterioration
The primary endpoint was a 
composite of death, reinfarction, 
stroke, or new ischemia at 12 months. 
The primary endpoint was reached in 
28 patients (21%) in the early invasive 
group compared with 36 (27%) in the 
conservative group (hazard ratio:
0.72, 95% Cl: 0.44 to 1.18, p = 0.19). 
The composite of death, reinfarction, 
or stroke at 12 months was 
significantly reduced in the early 
invasive compared with the
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conservative group (6% vs 16%, 
hazard ratio: 0.36, 95% Cl: 0.16 to 
0.81, p = 0.01). No significant 
differences in bleeding or infarct size 
were observed
Immediate transfer for PCI did not 
improve the primary outcome 
significantly, but reduced the rate of 
death, reinfarction, or stroke at 12 
months in patients with STEMI, 
treated with thrombolysis and 
clopidogrel in areas with long transfer 
distances
Cantor et al. 
(2009)
TRANSFER
-AMI
TRIAL
N=105
9
Immediate 
transfer to 
PCI capable 
hospital 
within 6hrs 
post­
thrombolysis
Thrombolysis 
with rescue 
PCI or 
delayed 
angiography
The primary end point was the 
composite of death, reinfarction, 
recurrent ischemia, new or worsening 
congestive heart failure, or 
cardiogenic shock within 30 days. 
Cardiac catheterization was 
performed in 88.7% of the patients 
assigned to standard treatment a 
median of 32.5 hours after 
randomization and in 98.5% of the 
patients assigned to routine early PCI 
a median of 2.8 hours after 
randomization. At 30 days, the 
primary end point occurred in 11.0% 
of the patients who were assigned to 
routine early PCI and in 17.2% of the 
patients assigned to standard 
treatment (relative risk with early PCI, 
0.64; 95% Cl: 0.47 to 0.87; p=0.004). 
There were no significant differences 
between the groups in the incidence of 
major bleeding. Among high-risk 
patients who had a myocardial 
infarction with ST-segment elevation 
and who were treated with 
thrombolysis, transfer for PCI within
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6 hours after thrombolysis was 
associated with significantly fewer 
ischemic complications than was 
standard treatment.
McKay et al. 
(2009)
N=155
3
PPCI Facilitated
PCI
Compared with patients who 
underwent primary PCI, the facilitated 
PCI group had longer door-to-balloon 
times (162 +/-57 vs 113 +/-61 
minutes), higher baseline infarct- 
vessel TIM I3 flow rates (52.8% vs 
25.4%; p <0.001), and no increase in 
major adverse in-hospital outcomes.
In patients treated with door-to- 
balloon times greater than 90 and less 
thanl50 minutes, patients who 
underwent facilitated PCI had fewer 
composite major adverse clinical 
events (combined mortality, recurrent 
myocardial infarction, emergent 
repeated PCI, hemorrhagic and non- 
hemorrhagic stroke, and non- 
intracranial TIMI major bleeding) 
compared with patients who 
underwent primary PCI (RR 0.50,
95% Cl 0.26 to 0.96, p=0.034)
Facilitated PCI can be safely used to 
increase pharmacological reperfusion 
before catheter-based therapy in 
patients with STEMI without an 
increase in clinical hazard and with 
fewer major adverse clinical events in 
patients treated with door-to-balloon 
times greater than 90 and less than 
150 minutes
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Appendix H: GRACE Risk Score Studies Summarized
Study Patient/
Pop.
Measure Result Conclusion
Yanet
al.
(2004)
4627 Examined the 
relationship
between in-hospital 
revascularization 
and 1-year outcome
among patients 
with non-ST- 
elevation ACS, 
stratified by the
GRACE risk score
In-hospital mortality 
rates were 2.4% overall 
and 1.5% among the 
patients with non-ST- 
elevation ACS (n = 
2925; 63.2%) in our 
validation cohort. Both 
the in-hospital 
PURSUIT and GRACE 
risk models showed 
similar and good 
prognostic
discrimination (57.8% 
Cl: 0.84 and 0.83, 
respectively; p = .69 for 
difference). The 
GRACE model also 
demonstrated good 
calibration (Hosmer- 
Lemeshow P = .40). In 
contrast, calibration in 
the PURSUIT model 
was poor (Hosmer- 
Lemeshow p < .001), 
with consistent 
overestimation of risks
High-risk patients with ACS 
appear to benefit from, but 
are less likely to undergo, 
early PCI. Used with sound 
clinical judgment, the 
GRACE risk stratification 
tool can facilitate an 
evidence-based approach that 
tailors treatment 
appropriately to the 
individual patient
Araujo 
et al. 
(2005)
460 Compared the 
prognostic value of 
three ACS risk 
scores (RSs) and 
their ability to 
predict benefit 
from myocardial 
revascularization 
performed during
460 consecutive 
patients admitted to 
coronary care unit with 
an ACS [age: 63±11 
years, 21.5% female, 
55% with myocardial 
infarction (MI)]. For 
each patient, the 
Thrombolysis In
The GRACE risk score 
demonstrates good 
predictive accuracy for death 
or MI at 1 year and enabled 
the identification of high-risk 
subsets o f patients who will 
benefit most from myocardial 
revascularization performed 
during initial hospital stay
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initial
hospitalization
Myocardial Infarction 
(TIMI), Platelet 
glycoprotein Ilb/IIIa in 
Unstable angina: 
Receptor Suppression 
Using Integrilin 
(PURSUIT), and 
Global Registry of 
Acute Coronary Events 
(GRACE) RSs were 
calculated using 
specific variables 
collected at admission. 
Their prognostic value 
was evaluated by the 
combined endpoint of 
death or MI at 1 year. 
The best cut-off value 
for each RS, calculated 
with receiver operating 
characteristic curves, 
was used to assess the 
impact o f myocardial 
revascularization on the 
combined incidence of 
death or MI. Death or 
MI at 1 year was 15.4% 
(32 deaths/49 Mis). The 
best predictive accuracy 
for death or MI at 1 
year was obtained by 
the GRACE risk score 
(Cl: 0.672-0.756) but 
the performance of the 
PURSUIT risk score 
(Cl: 0.584-0.674), and 
TIMI risk score (Cl: 
0.539-0.631) was also 
good. A statistically 
significant interaction
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between the risk 
stratified by the best 
cut-off value for the 
GRACE and PURSUIT 
risk scores and 
myocardial
revascularization, with 
a better prognosis for 
the high-risk patients 
was found. The high- 
risk patients represented 
the population as 
follows; GRACE 
(36.7%), PURSUIT 
(28.7%), and TIMI 
(57.8%)
Alter et
al.
(2006)
3500 To validate the 
Global Registry of 
Acute Coronary 
Events (GRACE) 
risk-adjustment 
index for 6-month 
all-cause mortality 
across
socioeconomic
strata
Predicted and observed 
mortality rates were 
significantly higher 
among patients of lower 
incomes and education 
(ie, observed 6-month 
mortality: 5.1 % vs 
1.8% among low 
income vs high income 
patients, respectively, 
p<.0001; 4.6% vs 2.9% 
among low-educated vs 
highly educated 
patients, respectively, 
p=.02). The predicted 
6-month mortality as 
derived using GRACE 
closely mirrored 
observed mortality rates 
with strong accuracy 
and precision (Cl: 0.80 
for the overall cohort 
and within each income 
and education strata;
The GRACE risk score for 6- 
month all-cause mortality is 
an accurate, well-calibrated, 
and robust predictor across 
socioeconomic strata and can 
be used as a valid risk- 
adjustment index when 
examining socioeconomic- 
mortality differences after 
acute Ml
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Hosmer-Lemeshow 
goodness-of-fit test was 
not significant within 
each income and 
education strata)
Bradsha 
w et al. 
(2006)
12875 To determine the 
validity of the 
GRACE prediction 
model for death six 
months after 
discharge in all 
forms of acute 
coronary syndrome 
in an independent 
dataset of a 
community based 
cohort of patients 
with acute 
myocardial 
infarction (AMI)
Post-discharge crude 
mortality at six months 
for the EFFECT study 
patients with AMI was 
7.0%. The
discriminatory capacity 
of the GRACE model 
was good overall (Cl: 
0.80) and for patients 
with ST segment 
elevation AMI 
(STEMI) (0.81) and 
non-STEMI (0.78). 
Observed and predicted 
deaths corresponded 
well in each stratum of 
risk at six months, 
although the risk was 
underestimated by up to 
30% in the higher range 
of scores among 
patients with non- 
STEMI
In an independent validation 
the GRACE risk model had 
good discriminatory capacity 
for predicting post-discharge 
death at six months and was 
generally well calibrated, 
suggesting that it is suitable 
for clinical use in general 
populations
Fox et
al.
(2006)
24189 To determine 
whether
revascularisation is 
more likely to be 
performed in 
higher-risk patients 
and whether the 
findings are 
influenced by 
hospitals adopting 
more or less
Overall, 32.5% of 
patients with a non-ST 
elevation ACS 
underwent
percutaneous coronary 
intervention (PCI; 
53.7% in ST segment 
elevation myocardial 
infarction (STEMI) and 
7.2% underwent 
coronary artery bypass
A risk-averse strategy to 
angiography appears to be 
widely adopted. Proceeding 
to PCI relates to referral 
practice and angiographic 
findings rather than the 
patient’s risk status. 
Systematic and accurate risk 
stratification may allow 
higher-risk patients to be 
selected for revascularisation
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aggressive
revascularization
strategies
grafting (CABG; 4.0% 
in STEMI). The 
cumulative rate o f in- 
hospital death rose 
correspondingly with 
the GRACE risk score 
(variables: age, Killip 
class, systolic blood 
pressure, ST-segment 
deviation, cardiac arrest 
at admission, serum 
creatinine, raised 
cardiac markers, heart 
rate), from 1.2% in low- 
risk to 3.3% in 
medium-risk and 13.0% 
in high-risk patients (c 
statistic = 0.83). PCI 
procedures were more 
likely to be performed 
in low- (40% non- 
STEMI, 60% STEMI) 
than medium- (35%, 
54%) or high-risk 
patients (25%, 41%).
No such gradient was 
apparent for patients 
undergoing CABG. 
These findings were 
seen in STEMI and 
non-ST elevation ACS, 
in all geographical 
regions and irrespective 
of whether hospitals 
adopted low 
(4.2233.7%, n = 7210 
observations), medium 
(35.7251.4%, n = 7913 
observations) or high 
rates (52.6277.0%, n =
procedures, in contrast to the 
current international practice
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8942 observations) of 
intervention
Ramsay 
et al. 
(2007)
347 To determine the 
predictive 
accuracies of the 
GRACE risk score, 
the TIMI risk score 
and clinical 
evaluation in 
unselected patients 
with suspected 
cardiac pain
Overall 54 patients 
(15.6%) experienced a 
major cardiac event (16 
deaths, seven 
myocardial infarctions 
(Mis), one emergency 
revascularization) or 
emergency re­
admission (n=30) 
within 3 months. Both 
GRACE (p< 0.001) and 
TIMI scores (p< 0.001) 
predicted
death/MI/revascularizat 
ion (and the composite 
including re­
admission), but the 
GRACE score was 
superior to the TIMI 
score for predicting 
major cardiac events (z. 
2.05), and both scores 
were superior to clinical 
evaluation (ROC areas 
0.82, 0.74 and 0.55 
respectively). The 
GRACE score predicted 
an ACS discharge 
diagnosis (p< 0 .001) 
and duration of hospital 
stay (p< 0 .001)
In unselected patients 
presenting with suspected 
cardiac pain, the GRACE 
risk score is superior to the 
TIMI risk score in predicting 
major cardiac events, and 
both risk scores are superior 
to using ECG and troponin 
findings at presentation
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Tang et 1143 To determine
al. whether GRACE is
(2007) a validated risk
model to predict 
mortality beyond 6 
months
39% had ST-elevation 
myocardial infarction, 
39% had non-ST- 
elevation infarction, 
and 22% had unstable 
angina. The mortality 
was 7.5% during index 
admission, 12.1% at 6 
months, 14.8% at 1 
year, 18.7% at 2 years, 
25.0% at 3 years, and 
39.2% at 4 years. The 
GRACE hospital 
discharge risk score 
calculated for 1057 
hospital survivors 
discriminated survival 
from death at 6 months 
(Cl: 0.81), 1 year (C 
index, 0.82), 2 years 
(Cl; 0.81), 3 years (Cl; 
0.81), and 4 years (Cl: 
0.80). The risk score 
worked for all 3 subsets 
of ACS at all time 
points, with Cl: 0.75 in 
all analyses. A separate 
multivariable mortality 
model for these 1057 
patients over the 4- 
years follow-up period 
identified 10 
independent predictors 
of mortality. Seven 
were in the GRACE 
risk model (age, history 
of ischemic heart 
disease, heart failure, 
increased heart rate on 
admission, serum
The GRACE post-discharge 
risk score contains relevant 
prognostic factors and was 
found to accurately 
discriminate survivors from 
non-survivors over the longer 
term (up to 4 years) in all 
subsets of ACS patients
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creatine level, evidence 
of myonecrosis, not 
receiving in-hospital 
PCI).
Yan et 
al.
(2007)
4144 To examine the use 
of in-hospital
cardiac
catheterization and 
medications in 
relation to risk
across the broad 
spectrum of non- 
ST elevation ACSs
Although in-hospital 
mortality rates were 
similar, the in-hospital 
use of cardiac 
catheterization 
increased significantly 
over time (38.8% in the 
ACS 1 Registry vs 
63.5% in the ACS 2 
Registry; p=.001). The 
rates of cardiac 
catheterization in the 
low-, intermediate-, and 
high-risk groups were 
48.0%, 41.1%, and 
27.3% in the ACS 1 
Registry, and 73.8%, 
66.9%, and 49.7% in 
the ACS 2 Registry, 
respectively (p=.001 for 
trend for both). After 
adjusting for other 
confounders, 
intermediate-risk 
(adjusted odds ratio, 
0.75; 95% Cl: 0.63- 
0.90; p=.001) and high- 
risk (adjusted odds 
ratio, 0.35; 95% Cl: 
0.28-0.45; p=.001) 
patients remained less 
likely to undergo 
cardiac catheterization 
compared with low-risk 
patients. Furthermore, 
there existed a similar
Despite temporal increases in 
the use of cardiac 
catheterization and 
revascularization in the 
management of non-ST 
elevation ACS, evidence- 
based invasive and 
pharmacological therapies 
remain paradoxically targeted 
toward low-risk patients. 
Strategies to eliminate this 
treatment-risk paradox must 
be implemented to fully 
realize the benefits and 
optimize the cost 
effectiveness of invasive 
management
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inverse relationship 
between risk and the 
use of in-hospital 
revascularization
Aragam 
et al. 
(2009)
3451 To compare the 
discriminative 
abilities of the 
TIMI and GRACE 
risk scores in a 
broad-spectrum, 
unselected ACS 
population and to 
assess the relative 
contributions of 
model simplicity 
and model 
composition to any 
observed 
differences 
between the two 
risk models
UA/NSTEMI (n =
2753) and STEMI (n = 
698) The predictive 
abilities of the TIMI 
and GRACE scores for 
in-hospital and 6-month 
mortality were assessed 
by calibration and 
discrimination. There 
were 137 in-hospital 
deaths (4%), and among 
the survivors, 234 
(7.4%) died by 6 
months post-discharge. 
IntheUA/NSTEMI 
population, the GRACE 
risk scores 
demonstrated better 
discrimination than the 
TIMI UA/NSTEMI 
score for in-hospital (C 
= 0.85, 95% Cl: 0.81- 
0.89, vs 0.54, 95% Cl: 
0.48-0.60; p=0.01) and 
6-month (C = 0.79,
95% Cl: 0.76-0.83, vs 
0.56, 95% Cl: 0.52- 
0.60; p=0.01) mortality. 
Among STEMI 
patients, the GRACE 
and TIMI STEMI 
scores demonstrated 
comparably excellent 
discrimination for in- 
hospital (C = 0.84, 95% 
Cl: 0.78-0.90 vs 0.83,
The GRACE scores provided 
superior discrimination as 
compared with the TIMI 
UA/NSTEMI score in 
predicting in-hospital and 6- 
month mortality in 
UA/NSTEMI patients, 
although the GRACE and 
TIMI STEMI scores 
performed equally well in 
STEMI patients. The 
observed discriminative 
deficit of the TIMI 
UA/NSTEMI score likely 
results from the omission of 
key risk factors rather than 
from the relative simplicity 
of the scoring system
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95% Cl: 0.78-0.89; p = 
0.83) and 6-month (C = 
0.72, 95% Cl: 0.63- 
0.81, vs 0.71,95% Cl: 
0.64-0.79; p = 0.79) 
mortality. An analysis 
of refitted multivariate 
models demonstrated a 
marked improvement in 
the discriminative 
power of the TIMI 
UA/NSTEMI model 
with the incorporation 
of heart failure and 
hemodynamic variables
Elbarou 
ni et al. 
(2009)
12242 To validate the 
GRACE risk score 
in a contemporary 
Canadian 
population with 
ACS
A total of 12,242 
Canadian patients with 
ACS were included; the 
median GRACE risk 
score was 127 (25th and 
75th percentiles were 
103 and 157, 
respectively). Overall, 
the GRACE risk score 
demonstrated excellent 
discrimination (c 
statistic 0.84, 95% Cl 
0.82-0.86, p= .001) for 
in-hospital mortality. 
Similar results were 
seen in all the 
subgroups (all c 
statistics >0.8). 
However, calibration 
was suboptimal overall 
(Hosmer-Lemeshow p= 
.06) and in various 
subgroups
GRACE risk score is a valid 
and powerful predictor of 
adverse outcomes across the 
wide range of Canadian 
patients with ACS. Its 
excellent discrimination is 
maintained despite advances 
in management over time and 
is evident in across all patient 
subgroups. However, the 
predicted probability of in- 
hospital mortality may 
require recalibration in the 
specific health care setting 
and with advancements in 
treatment.
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Gale et 100886 To compare the The C-indexes were: The five ACS risk models
al. discriminative PURSUIT C-index 0.79 (p u r s u it ,g u s t o - i ,
(2009) performance o f the (95% Cl 0.78 to 0.80); GRACE, SRI, EMMACE)
PURSUIT, GUSTO-1 0.80 (0.79 to maintained their
GUSTO-1, 0.81); GRACE in- discriminative performance
GRACE, SRI and hospital 0.80 (0.80 to in a large unselected English
EMMACE risk 0.81); GRACE 6-month and Welsh ACS population,
models, assess their 0.80 (0.79 to 0.80); SRI but performed less well in
performance 0.79 (0.78 to 0.80); and higher-risk sub groups.
among risk EMMACE 0.78 (0.77 Simpler risk models had
supergroups and to 0.78). EMMACE comparable performance to
evaluate the maintained its ability to more complex risk models
EMMACE risk discriminate 30-day
model over the mortality across
wider spectrum of different ACS
acute coronary diagnoses
syndrome (ACS)
Recalibration of the 
model offered no 
notable improvement in 
performance over the 
original risk equation. 
For all models the 
discriminative 
performance was 
reduced in patients with 
diabetes, chronic renal 
failure or angina
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Abu- 
Assi et 
al. 
(2010)
N=1183 To assess the 
validity of the 
GRACE risk score 
in a contemporary 
cohort of patients 
admitted to a 
Spanish hospital
In total, 459 (38.8%) 
patients were admitted 
for ST-elevation 
myocardial infarction 
(STEMI) and 
724(61.2%) for non- 
ST-elevation 
myocardial infarction 
(NSTEMI). PCI was 
performed in 846 
(71.5%). The median 
GRACE risk score was 
121[IQR, 96-144], 
Mortality 6 months 
after discharge was 
4.4%. The calibration 
of the GRACE risk 
score was acceptable 
(Hosmer-Lemeshow, 
P>.2) and its 
discriminatory capacity 
was excellent: the area 
under the curve was 
0.86 (95% Cl: 0.807- 
0.916) for all patients, 
0.9 (95% Cl: 0.829- 
0.975) for those with 
STEMI and 0.86 (95% 
Cl: 0.783-0.927) for 
those with NSTEMI
The GRACE risk score for 
predicting death within 6 
months of hospital discharge 
was validated and can be 
used in patients with ACS. It 
would be wise to include the 
GRACE risk score in the 
medical records of these 
patients
Stacke 
et al. 
*2010)
N=1014 To evaluate the 
relationship 
between the 
GRACE risk score 
and in-hospital 
mortality in 
patients presenting 
to the ED with 
chest pain of all
A total of 94 patients 
died during the stay in 
the hospital, 83 patients 
with high risk, 9 with 
medium risk, and 2 
with low risk. The risk 
of in-hospital death was 
24.5% for high-risk 
patients, 2.6% for 
medium-risk patients,
This study shows that the 
GRACE risk score accurately 
stratifies risk of intra-hospital 
mortality in patients 
presenting to the ED with 
chest pain and can help guide 
patient triage and 
management
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causes and 0.6% for patients 
with low risk. The 
correlation between the 
GRACE risk score and 
in-hospital mortality is 
strongly positive
(p=0.01).
Koziera 
dzka et 
al. 
(2011)
N= 505 To test the of 
GRACE risk score 
prognosis of 5-year 
survival in a “real- 
life” population of 
patients with ST- 
elevation 
myocardial 
infarction (STEMI) 
treated with PPCI
32 patients died during 
the first 30 days (6.3%) 
and an additional 74 
within 5 years (15.6%). 
PCI was successful in 
95.2%(n = 481). 
Prognostic values (c 
statistics) for predicting 
5-year mortality 
equaled: 0.742 (Cl: 
0.69-0.79) for the 
GRACE risk score, 
0.727 (Cl 0.67-0.78) 
for TIMI, 0.72 (Cl: 
0.67-0.77) for Zwolle, 
and 0.687 (Cl 0.63- 
0.74) for CADILLAC. 
Univariate analysis all 
the scores were 
associated with the 5- 
year outcome.
GRACE, TIMI, and Zwolle 
risk scores predicted well 5- 
year all-cause mortality in 
patients with STEMI treated 
with PPCI. The data show 
that the usefulness of initial 
bedside risk assessment can 
be further extended for long­
term follow-up
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